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Abstract 
Biosensing systems that detect and quantify biomolecules at ultra-low concentration, 
with point of care settings, are of great need in many fields, including diagnostics, disease 
control, general health monitoring and fundamental research. Over the past decade, 
detection of biomolecule using magnetic biosensing system, which combines giant 
magnetoresistive (GMR) sensors and magnetic particles, has been attracting a lot of 
attention in biosensing area, due to the potential advantages on portability, low cost and 
rapid detection. This dissertation presents a novel magnetic biosensing system, consisting 
of highly sensitive GMR sensor and high-moment FeCo magnetic nanoparticle. Based on 
competition-based detection scheme, this system successfully demonstrates the 
quantification of ultralow concentration of biomarkers under a small magnetic field in 
real human serum/urine samples, and differentiates the patients with different grades of 
cancers. 
One of the key factors to achieve detection of biomarkers in ultralow concentration is 
the sensitivity of the GMR biosensor. We designed and fabricated a GMR sensor with a 
near 0-degree ground state for the magnetization directions between pinned layer and free 
layer. This configuration enables three times greater sensitivity than any reported 
traditional GMR biosensor design, and requires much smaller polarization working field 
(10 Oe) which is more suitable for lab-on-chip and portable diagnostics. 
Another key factor to increase the system sensitivity is to enhance the magnetic signal 
of magnetic label. High-magnetic-moment FeCo nanoparticles with great homogeneity, is 
 v 
 
proposed and synthesized for biomedical application. The net magnetic moment of a 
FeCo nanoparticle is seven times higher than that of a commercial available Fe3O4 
nanoparticle with an applied field of 10 Oe, assuming the same particle size. Moreover, 
the high homogeneity of FeCo nanoparticle enables the accurate quantification of low-
abundance biomarkers.  
Combining the novel GMR biosensor and high-moment FeCo magnetic nanoparticle, 
the accurate quantification of various biomarkers in real human serum/urine sample is 
demonstrated. To assist the high sensitivity quantification, two-layer/three-layer based 
competition detection schemes are developed. The low concentration interleukin-6 in 
unprocessed human sera, down to 200 copies, has been detected in only 5 minutes 
processing time. Based on the results, normal individuals and lung cancer patients were 
nicely identified. Moreover, the detection of as few as 1000 copies of endoglin is 
demonstrated in human urine samples. Based on the endoglin concentrations, the patients 
with different grades of prostate cancer are successfully differentiated. 
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 Introduction Chapter 1
1.1 Introduction 
Ultra-low concentration detection of biomolecules, such as proteins and DNAs, is 
highly desired for early detection of cancer and chronic diseases
1-7
 when the biomarkers 
are only present in very low level. On the other hand, longitudinally monitoring
8-14
 the 
changes of protein biomarkers is expected to help design medical treatment for specific 
individuals, which requires low-cost and easy-to-use medical devices
15-18
. Traditionally, 
fluorescence-based biosensors, such as enzyme-linked immunosorbent assays (ELISAs
19-
21
), have been widely used in biomedical research and clinic for biosensing, although are 
only able to detect abundant of proteins. The main problems associated with 
fluorescence-based biosensors include lack of quantitative analysis, long processing time, 
expensive equipment and low signal-to-noise ratio due to the large optical background 
which limits the sensitivity
22
. Over the past ten years, magnetoresistive biosensors 
incorporated with magnetic labels (microbeads or nanoparticles) have become a 
promising candidate for biosensing due to the advantages of high sensitivity and low-
cost. since such a system has the unique merits, including portability
23-25
, low cost
26
, 
rapid detection
27
, ease for integration into lab-on-chip systems
28
, and lack of magnetic 
background in biological samples. In this chapter, various biosensing techniques will be 
reviewed and discussed. 
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1.2 Optical biosensing 
Optical biosensor has been widely employed, and is still one of dominant biosensors 
in various applications, such as clinical study
29
, environmental monitoring
30
, drug 
delivery
31
 and warfare
32
. These applications are enabled by its advantages of 
insusceptible to electromagnetic field, low cost, easy for multiplexing and real time 
detection. On the other hand, optical biosensor also suffers in various aspects, for 
example, strong interference with light which leads to low signal to noise ratio and 
complicated/expensive setup to achieve high sensitivity. Although light is measured as 
output transduced signal for optical biosensor, based on detection principle, optical 
biosensor can be classified into two major categories: labeled and label-free detection.  In 
labeled optical biosensing system, analyte of interest is typically bond to a light signal 
source directly or indirectly, such as fluorescence or phosphorescence, where the 
emission or absorbance of light with certain wavelength is monitored. Alternatively in 
label-free optical biosensor, the sensing signal is generated from the change of 
reflection/interference/evanescent field resulted from bioreaction. Ellipsometry, 
interferometry, surface plasmon resonance and optical waveguide, are most commonly 
used techniques in label free optical detection. In the following sections, various optical 
biosensing techniques are reviewed and discussed.  
Chapter 1 Introduction 
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1.2.1 Fluorescent detection 
Fluorescence, also called fluorophores or fluors, is by far the most often used optical 
method for biosensing. A typical fluorescent detection involves three stages: 1) 
absorbance; 2) excitation and 3) emission. Jablonski described the process using a 
diagram in 1993, later being called Jablonski diagram
33
. As shown in Figure 1.1, when a 
photon from excitation source is absorbed by fluorophore, an electron of fluorophore will 
be excited from ground state to excited state. There is a finite lifetime for the excited 
state, typically several nanoseconds, during which the excited electron consumed its 
partial energy due to the interaction with the molecular environment. In the last stage, the 
electron returns back to ground energy state and at the same time emits a photon. Due to 
the energy consumption in the second stage, the emitted photon has less energy than the 
injected one, thereby longer wavelength. As a result, the excitation light can be 
distinguished from the emitted florescent light.  
The wavelength difference between excitation and emission is called stokes shift, 
which is a unique characteristic of each fluorescence. Preferably, a good fluorescent 
candidate should have large enough stoke shift, so that the wavelengths of excitation and 
emission light don’t overlap with each other. The stoke shift characteristic is the key in 
multiplexing application, where multiple emission lights are excited and differentiated.  
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Figure 1.1 Jablonski energy diagram of fluorescence. 
DNA microarray is one of the most important applications for fluorescent detection
34-
37
. In the past decade, the development of DNA microarray has been motivated by many 
areas, such as gene expression profiling and comparative genomic hybridization. One of 
the most common DNA microarrays is to employ fluorescent labeled complimentary 
DNA (cDNA) for the detection. Figure 1.2 illustrates an example of using cDNA to 
investigate gene expression from yeast cell
38
. To start with, messenger RNAs (mRNAs), 
which are generated from the segmental copy of active gene, from both vegetative and 
sporulating yeast cells are collected. The mRNA produced by the yeast cells is 
complementary to certain original portion of the DNA strand. Next, by using reverse 
transcription, the complementary DNA to each mRNA is generated, during which the 
Chapter 1 Introduction 
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florescent labels are attached to cDNA. In this case, vegetative yeast is labeled with green 
florescence, while sporulating yeast is labeled with red florescence. The florescent 
labeled cDNAs then are transferred and hybridized with DNA microarray, which 
containing the synthetic complimentary DNAs. Once the hybridization finishes, one can 
measure florescent light intensity from DNA microarray scan. The results reflect ratio of 
mRNAs from both sporulating yeast and vegetative yeast.  
      
Figure 1.2 DNA microarray for yeast cell gene expression analysis. 
An DNA microarray could hold up to thousands of spots with size of tens to hundreds 
of micrometers
39
. The array production can be either achieved by an auto spotting robots 
or photolithographic process. Affymetrix developed a process using photolithography and 
solid-phase DNA synthesis to construct DNA probe array, with a density as high as 
Chapter 1 Introduction 
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approximately 300,000 polydeoxynucleotides on a 1.28 cm x 1.28 cm array
40
. With such 
high density and throughput, DNA microarray provides a powerful and efficient tool for 
genetic and cellular analysis. 
Despite all the promising aspects discussed above, fluorescent detection has its own 
limitations, such as photobleaching. Being excited under high intensity light source or 
exposed to multiple detections, the fluorescent effect may be destructed irreversibly, 
which is called photobleaching. The root cause for photobleaching can be quite complex 
involving several different mechanisms
41
. Usually the hypothesis of multiple 
photochemical reaction pathways is referred to the main reason. Meanwhile, to achieve 
high detection sensitivity, fluorescent detection typically requires expensive and 
stationary laser system, as well as scanner. Therefore, other biosensing technologies, such 
as surface plasma resonance from same optical area and magnetic biosensing, are also 
being explored.        
1.2.2 Surface plasma resonance 
Surface plasma resonance (SPR) is a process, where the photons of incident polarized 
light couple with the free electrons (surface plasmons) at the interface between materials 
with negative and positive permittivity. This phenomenon was first observed by Wood
42
 
(initially named Wood’s anomaly) in 1902, when he discovered the anomalous change of 
diffraction energy from metallic gratings. The process creates an electromagnetic field, 
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while at total excitation it generates a strong evanescent field which propagates along the 
interface. Since the evanescent field is very sensitive to the dielectric properties of the 
interface, surface plasma resonance has been widely used in microscopy
43,44
, 
plasmonics
45-47
, as well as biomedical applications
48-50
. 
To generate SPR, most of the current commercial SPR systems, such as Biacore, 
Spreeta and Optrel, employ prim coupling configuration proposed and developed by 
Otto
51
 and Kretschmann
52
. Prism coupling based SPR sensor typically consists of an 
optical medium (such as prism), and a thin metal layer (such as gold), as shown in Figure 
1.3 (a)
49
. A charge density oscillation could be generated at the interface, due to the 
opposite signs of dielectric constants of the prism and gold thin film. With the incident 
light, the charge density oscillation will couple with the plasma oscillation of the 
electrons in the metal, generating an evanescent field. In this configuration, when 
reaching the attenuated total reflection (ATR), the evanescent field generated by the 
incident light has the strongest intensity, while the reflectance shows a dip in the reflected 
light spectrum (Figure 1.3 (b)). With the binding of biomolecules, such as surface 
receptors or analyte, the evanescent field will strongly interact with the newly added 
bimolecular layers. Therefore, the dielectric property of the interface will be changed, so 
that the dip of reflectance will be shifted, or the reflected intensity will be changed. Such 
shift or intensity change, can be then measured by an external detector at the same time, 
which is the identifier of the bio-binding process. Although offering great sensitivity, 
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prism coupling configuration has challenge in device miniaturization and integration, due 
to the relatively large size of optical medium and detection system. 
 
Figure 1.3 (a) Prism coupling SRP configuration; (b) resonance swift in the reflected 
light spectrum 
 Besides the prism coupling, some other SPR configurations are also studied. The 
main principle of other SPR configurations is similar to that of prism coupled SPR, 
except replacing prism with other optical medium, which would couple the incident light 
with the surface plasmons at interface. Jorgenson et al.
53
 proposed optical fiber coupled 
SPR sensing in 1993. In this SPR configuration (Figure 1.4), an optical fiber, which can 
be single-mode
54
 or multimode
55
, is used to guide the incident light through the fiber by 
total internal reflection. The detection could happen at the fiber tips where the reflected 
light or diffracted light is measured, which is similar to the prism coupled method. At the 
fiber tips, evanescent field is also excited by the interaction between incident light and 
Chapter 1 Introduction 
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the surface plasmons, which would be used for the detection of bio-bonding process. The 
advantage of waveguide coupled SPR over prism coupled SPR is unlike the bulky setup 
with prism coupled SPR, the feasibility for device miniaturization.  
 
Figure 1.4 Schematic showing of three fiber-optic sensor configurations: a) polished 
end; 2) micro-prism end; 3) cladding-removed 
1.3  Magnetic biosensing 
The discovery of giant magnetoresistive (GMR) effect by Fert
56
 and Grunberg
57
, who 
was rewarded by Noble Prize in physics 2007, boosts the development of magnetic 
storage industry, as well as creating a new emerging area of spintronics. Recently, GMR 
or magnetic tunneling junction (MTJ) based biosensors have attracted increasing interest 
in the world. This technique uses GMR/MTJ sensors to detect the stray magnetic fields 
associated with the magnetic labels bonded with the biomolecules. In this section, 
magnetoresistive based biosensor will be reviewed and discussed. 
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1.3.1 GMR effect 
GMR effect is a phenomenon that the resistance of the device changes under the 
application of magnetic field. Typically, the term of magnetoresistance (MR) is used to 
characterize the amount of the resistance change with the magnetic field. MR can be 
expressed by: 
   
 ( )   
  
 
where R(H) is the resistance of the device with magnetic field H, and R0 is the resistance 
without magnetic field. Magnetoresistance may originate from different mechanisms 
other than GMR, such as colossal magnetoresistance (CMR), anisotropic 
magnetoresistance (AMR) or tunneling magnetoresistance (TMR).  
GMR was first reported experimentally by Fert
56
 and Grunbery
57
 independently in 
1988. As shown in Figure 1.5, Fert et al. demonstrated nearly 50% of MR change using 
the (001)Fe/(001)Cr supperlattice structure prepared by molecular beam epitaxy, under 
2T magnetic field and a low temperature of 4.2K. On the other hand, Grunbery also 
reported 10% of MR change from Fe-Cr-Fe layers with antiferromagnetic interlayer 
exchange, under around 0.35T and 5K temperature. Historically, before the discovery of 
GMR, the observed highest MR change was from AMR effect, which is around a few 
percentages. Therefore, the word “giant” was used by Fert to distinguish the large MR 
change comparing to AMR effect.  
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In theory, GMR effect can be explained by Mott’s two current model58, which was 
published in 1936 to qualitatively understand the sudden change of resistivity in 
ferromagnetic metals around Curie temperature. In his model, Mott proposed that, 1) the 
electron transport exists for both up-spin and down-spin independently in ferromagnetic 
material, and 2) electron scattering in ferromagnetic layer is strongly spin dependent. One 
assumption is that the mean free path of the electron is much longer than the thickness of 
the layers. Therefore, in a ferromagnetic/non-magnetic/ferromagnetic (FM/NM/FM) 
structure as shown in Figure 1.6 (a), one can assume the electron scattering is weak for 
up-spin with magnetization direction, while is strong in the case of down-spin. When the 
magnetizations of two ferromagnetic layers are parallel, up-spin encounters less electron 
scattering in both ferromagnetic layers, which results in smaller resistivity in both layers. 
On the other hand, down-spin, due to the spin dependent scattering, experiences more 
electron scattering on both layers, which leads to higher resistivity in both layers. Hence, 
the equivalent resistance circuit is shown in the bottom of Figure 1.6 (a), and the 
resistance is  
   
    
     
 
where    is the device resistance of up-spin electrons, and    is the device resistance of 
down-spin electrons. For the antiparallel case, as shown in Figure 1.6 (b), both up-spin 
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and down-spin experience strong scattering in one of the ferromagnetic layers, where the 
resistance is 
   
     
 
 
therefore, the equivalent resistance in antiparallel configuration is higher than that of 
parallel configuration. In addition, the MR can then be expressed by: 
   
      
  
 
       
 
     
 
 
Figure 1.5 Magnetoresistance of three Fe/Cr superlattices at 4.2K 
The current and the applied field are long the same [110] axis in the plane of the layers  
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Figure 1.6 Schematic illustration of electron transport in a multilayer for parallel (a) 
and antiparallel (b) magnetizations of the successive ferromagnetic layers 
The solid lines are individual electron trajectories 
1.3.2 Spin valve structure 
The GMR device is quite complex and functional only under large applied field and 
low temperature, due to the antiferromagnetic coupling between the multilayers. Such 
restrictions prevent the wide application of GMR device where small magnetic field and 
nominal/high temperature are needed. In 1991, spin valve structure
60
 was proposed by 
Dieny et al. In the spin valve structure (Figure 1.7), a non-magnetic metal layer (also 
called spacer) is sandwiched between two ferromagnetic layers. The magnetization of one 
of the ferromagnetic layer is pinned by an antiferromagnetic (AFM) layer (such as IrMn, 
FeMn), which is also called fixed layer or pinned layer. Since it is pinned, the 
magnetization of fixed layer is not sensitive to the applied magnetic field, while the other 
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ferromagnetic layer is free to rotate with the application of external magnetic field. The 
resistance of the spin valve GMR sensor is high when the magnetizations of fixed and 
free layers are antiparallel and low when they are parallel. Therefore, the dynamic range 
of the spin valve GMR sensor typically depends on the anisotropy of the free layers. 
Figure 1.8 shows the around 4% MR response within +/- 50 Oe reported by Dieny et al. 
Since then, spin valve GMR sensor has been studied and researched intensively. One 
important application for spin valve GMR sensor is magnetic recording. Spin valve GMR 
sensor was used as read sensor in hard drive industry
61,62
, which increases areal density 
by three orders of magnitude (from ~0.1 to ~100 Gbit/in
2
) between 1991 and 2003, till 
the invention of TMR sensor. Other applications include magnetic field sensing, 
magnetic random access momery (MRAM), as well as magnetic biosensing, which will 
be discussed in later sections. 
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Figure 1.7 The schematic drawing of spin valve structure 
 
Figure 1.8 MR response of spin valve GMR sensor between +/- 50 Oe 
1.3.3 GMR biosensing 
In recent years, GMR or MTJ based biosensors are intensively studied. The first 
demonstration of magnetic biosensing system was done by Baselt et al. from Naval 
research lab
63
. As shown in Figure 1.9, this unit, which is called Bead ARray Counter 
(BARC), detects microsized magnetic beads immobilized on the GMR sensor surface. 
Bruckl et al. employed a spiral-shaped GMR biosensor and concluded that the GMR 
biosensor has higher sensitivity than fluorescence-based biosensor
64
. Tondra et al. 
examined the theoretical signal to noise ratio of this type of assay and predicted the 
possibility of detection of magnetic nanoparticle labels
65
. Freitas et al. developed a 
prototype of hand-held microsystem based on fully integrated magnetic biosensors for the 
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first time
66
. Prins et al.
67
 and Boeck et al.
68
 first demonstrated the real-time on-chip 
detection and manipulation of microsized magnetic particle using microfabricated current 
wires. Wang et al. demonstrated a multiplex protein assay using 50 nm magnetic nanotag 
sensing
23
. Besides GMR biosensor, MTJ biosensor is another promising candidate due to 
its high MR ratio. Xiao et al. has shown the detection of DNA labeled magnetic 
nanoparticles using MgO based MTJ sensor
69
. Table 1-1 briefly summaries, up to date, 
different magnetic biosensing systems, from the aspects of sensor type/size, sensor 
working range, magnetic label/size and the application to biomarker detection. 
 
 
Figure 1.9 Prototype of BARC and detection principle 
(a) Protograph of a prototype of 64 magnetoresistive sensors, which is composed of 80 
× 20 µm GMR sensors 
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(b) Cross-section of a GMR sensor, illustrating the method used to detect 
superparamagnetic beads. 
 
Table 1-1 Summary of magnetoresistive sensor and magnetic labels  
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 Magnetic Biosensing System Design Chapter 2
2.1 Introduction  
There are typically three important components in a magnetic biosensing system: 1) 
magnetic biosensor; 2) magnetic label; 3) detection scheme. In this chapter, each essential 
component is discussed respectively. These results have been published as “Biomarkers 
identification and detection based on GMR sensor and sub 13 nm magnetic 
nanoparticles”, Li, Y. et al. in Engineering in Medicine and Biology Society, 2009. 
EMBC 2009. Annual International Conference of the IEEE.  5432-5435. 
2.2 Magnetic biosensor design 
Sensor design is always the key factor in a sensing system. The sensitivity and the 
detection range of a sensing system exclusively depend on the design of sensor. Majority 
of magnetic biosensing systems utilizes the linear sensor following the magnetic 
recording industry, which is reviewed in this section. Meanwhile, another type of 
biosensor design, hysteresis sensor is proposed and demonstrated in this thesis. The 
different magnetic biosensor properties of these two types of sensor designs, such as 
sensitivity and detection range, are discussed in the following sections.  
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Figure 2.1 Magnetization configuration and transfer curve of linear and hysteresis 
GMR sensor 
a) Traditional GMR configuration: 90 degree ground state for magnetization directions 
between free layer and pinned layer. b) Linear transfer curve for traditional GMR 
configuration. c) New GMR configuration: zero degree ground state. d) High sensitive 
transfer curve from zero degree ground state. (Mfree and Mpinned represent the 
magnetization directions of free layer and pinned layer, respectively) 
The sensitivity of the GMR biosensor is one of the key factors in the detection of low 
concentration biomarker. Currently, most of the GMR sensors reported have a 90 degree 
ground state for magnetization directions between free layer and pinned layer, as shown 
in Figure 2.1 (a). The transfer curve for this traditional configuration of the GMR sensor 
is shown in Figure 2.1 (b) as a red line. This orthogonal configuration originates from 
magnetic recording industry, where GMR sensor is used as a reader for sensing the 
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magnetic stray field from the spinning disk. While this design shows good linear signal 
output, the drawback is the requirement of large applied field (100 Oe or above) which 
limits its sensitivity and portability. To solve these problems, we proposed, designed and 
fabricated GMR sensor with zero degree ground state for magnetization direction 
between free layer and pinned layer shown in Figure 2.1 (c). Based on its transfer curve 
as shown in Figure 2.1 (d), hysteresis sensor design enables a higher sensitivity (dR/dH) 
and requires a much lower applied field compared to the traditional 90 degree 
configuration. Especially, the unique feature of low applied field makes this design more 
suitable for lab-on-chip and portable diagnostics. Figure 2.2 shows a fabricated GMR 
sensor with 3% MR and maximum sensitivity of 0.6 % MR per Oe near 10 Oe applied 
field. This sensitivity is three times higher than any traditional GMR sensor design that 
has been reported. 
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Figure 2.2 Transfer curve and sensitivity curve of GMR 
2.3 Magnetic label 
Magnetic biosensing is usually an indirect detection method since the biological 
sample (analyte) does not provide magnetic signal, except under very high magnetic field, 
such as nuclear magnetic resonance (NMR). Therefore, magnetic labels, like magnetic 
microbeads or nanoparticles, are needed to provide magnetic signal for sensor detection. 
Furthermore, there are several considerations for the design of magnetic label.  
First of all, magnetic label is required to be superparamagnetic to avoid the particle 
aggregation during sample preparation. The magnetization of superparamagnetic particle 
can be described by the Langevin function as 
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where   is the saturation magnetization,   is the saturation magnetic moment of a 
single particle,    is the magnetic permeability of vacuum,    is the applied magnetic 
field,    is the Boltzmann constant,   is the absolute temperature, and   is the Langevin 
function. Therefore, without any applied magnetic field, the net magnetization of a 
superparamagnetic particle is zero at room temperature, which prevents the unnecessary 
magnetic interaction between particles.  
Secondly, magnetic label with high magnetic moment under reasonable applied 
magnetic field is preferred. The way that magnetic label provides signal to magnetic 
biosensor is through magnetic dipole interaction. Therefore, higher magnetic moment, 
which is proportional to larger magnetic dipole field, would provide stronger magnetic 
signal to sensor. 
Thirdly, the size and homogeneity of magnetic label is very critical. Up to date, most of 
the reported magnetic labels are commercially available, and vary in size from 50nm to 
3μm. Due to the low diffusivity and poor binding selectivity, microsized magnetic labels 
are not favorable for biomolecule detection. On the other hand, nanosized magnetic 
labels, with similar size to biomarkers, are preferred in the application of magnetic 
biosensing. Figure 2.3 shows the summary of magnetic label size published in the past 
ten years. The arrow drawn for the guide of eye shows a clear trend indicating that 
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magnetic labels with smaller size become more preferred in the magnetic biosensing 
scheme. In recent few years (shown in the insert of Figure 2.3), sub 50nm magnetic labels 
have been integrated into the magnetic sensing system.  
 
Figure 2.3 Summary of size of magnetic labels used in the past ten years  
While most of research groups use commercial iron oxide nanoparticles with low 
magnetic moments, high moment FeCo magnetic nanoparticle is utilized for magnetic 
biosensing application in this dissertation,. The net magnetic moment of a 12.75 nm FeCo 
nanoparticle is 7 times higher than that of a commercially available γ-Fe2O3 nanoparticle 
at external field of 10 Oe, assuming the same nanoparticle size and 1.5 nm oxide shell for 
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FeCo nanoparticles. Figure 2.4 shows TEM image of 12.8 nm FeCo magnetic 
nanoparticles with a composition of 70:30 which were synthesized using a sputtering gas 
condensation technique
71
. The particle morphology and phase are precisely controlled by 
modifying the magnetic flux in the sputtering target. The prepared FeCo nanoparticles are 
dominantly cubic shaped. The nanoparticles are highly homogeneous as shown in Figure 
2.5, which is crucial for accurate biomolecule quantification. 
 
Figure 2.4 TEM image of cubic FeCo nanoparticles 
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Figure 2.5 Size distribution of FeCo nanoparticles 
2.4 Magnetic biosensing detection scheme 
Since magnetic biosensing is an indirect detection method, the detection scheme, 
which connects magnetic label to magnetic biosensor, is vital to whole system. 
Traditionally, there are two detection schemes: three-layer and two-layer. Figure 2.6 (a) 
demonstrates a three-layer structure based biomarker detection scheme using GMR 
biosensor and high moment FeCo magnetic nanoparticles. The capture antibodies are first 
immobilized on the positive GMR sensor surface. Then the samples with biomarkers, 
such as IL-6, are applied on GMR sensor surface under the binding condition. 
Subsequently, the detection antibodies modified by high moment FeCo magnetic 
nanoparticles are applied on the sensor surface. After thorough rinsing, the modified 
detection antibodies bind to the capture antibody-modified positive GMR biosensor, 
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contributing to the sensing signal picked up by the GMR biosensor underneath. This 
structure is typically referred as sandwich or three-layer structure. As shown in Figure 2.6 
(b), another detection scheme is to bypass the detection antibody, and directly bind the 
magnetic nanoparticle onto biomarker. This structure is referred as bilayer or two-layer 
structure. The advantage of this method is the magnetic signal would be higher since the 
magnetic nanoparticles are closer to magnetic biosensor. However, directly labeling 
biomarkers is not preferred, since it may contaminate the sample.  
To solve this problem, in this thesis, a competition based two-layer detection scheme 
is proposed. As shown in Figure 2.7, two-layer competition detection scheme starts with 
unprocessed sample and standard reference sample. The standard reference sample 
consists of the same target analyte as unprocessed sample, but with magnetic nanoparticle 
labeled purposely first. While applying both samples on sensor surface with detection 
antibodies, analytes with and without magnetic label would compete the limited binding 
sites of detection antibodies. Eventually, an equilibrium state can be achieved, when the 
amounts of both labeled and unlabeled analytes, which binds to the detection antibodies, 
stay unchanged. Under this circumstance, the magnetic signal from labeled analyte 
reflects not only the amount of labeled analyte binding to detection antibodies, but also 
the amount of unlabeled analyte binding to detection antibodies. Usually a dose response 
curve is established first with difference amount of known analyte concentrations. Later, 
the concentration of unlabeled analyte can extracted from the does response curve, based 
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on the magnetic signal from competition based detection scheme. The experimental 
results are discussed in Chapter 4.   
 
Figure 2.6 Two different GMR biosensor and magnetic nanoparticle-based 
biomolecule detection schemes.  
(A) Three-layer approach: the GMR biosensors are first functionalized with capture 
antibodies. The analyte spotted onto the GMR biosensor surface binds to the capture 
antibody. Subsequently, detection antibodies labelled with magnetic nanoparticles are 
then applied and bind to the captured analyte. (B) Two-layer approach: after the 
functionalization with capture antibodies, the magnetic nanoparticle modified analyte 
are directly applied and captured on the GMR biosensors. 
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Figure 2.7 Two-layer based competition detection scheme. 
The magnetic nanoparticle labeled analyte and unlabeled analyte are applied on the 
same capture antibody functionalized GMR biosensor and compete the binding sites. 
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 Sensor Fabrication and Measurement Chapter 3
3.1 Introduction 
In this chapter, the fabrication process of GMR biosensor is introduced first. The 
process steps consist of certain semiconductor fabrication techniques, such as thin film 
deposition, photo-lithography and dry etching (ion milling). Each main step is discussed 
respectively in this chapter. Furthermore, the measurement scheme of the sensing system 
is discussed.     
3.2 GMR thin film stack deposition 
The GMR magnetic biosensor is made of multilayer thin film structure which is 
deposited in high vacuum condition. The multiplayer stack consists of both metallic 
(magnetic and non-magnetic) and insulating layers, with only nanometers thickness.  
The GMR stack deposition starts from a silicon wafer, which has 100 nm pre-
deposition thermal oxide by using thermco mini brute. As shown in Figure 3.1, a 
multilayer GMR structure of Ta (5nm) /Ir0.8Mn0.2 (10nm) /Co0.9Fe0.1 (2.5nm) /Cu (3.3nm) 
/Co0.9Fe0.1 (1nm) /Ni0.82Fe0.12 (2nm) /Ta (5nm) was deposited on thermal oxide silicon 
wafer using a six-target Shamrock sputtering system
72
. Shamrock sputtering system 
utilizes the magnetron sputtering technique, which is a widely used physical vapor 
deposition (PVD) method for thin film deposition. In magnetron sputtering, the sputtering 
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target is bombarded by energetic ions, in this case, Ar
+
 ions, so that the sputtering 
material is ejected and deposited on the substrate. What makes the magnetron sputtering 
different from other general sputtering technique is that a magnetic field is used to 
constrain the secondary electron close to target, which increases the plasma density.  
During the film deposition, a magnetic field of around 50 Oe was applied to the main flat 
of the substrate wafer, in order to induce in-plane parallel easy axis. 
The detailed sputtering conditions of each layer are listed below (Ar pressure, 
sputtering power, bias voltage, sputtering time): 
Ta50: 50sccm Ar, 156W, 60V, 175sec 
IrMn80: 50sccm Ar, 257W, 30V, 140sec 
CoFe25: 25sccm Ar, 193W, 60V, 75sec 
Cu33: 45sccm Ar, 176W, 60V, 17sec 
CoFe10: 25sccm Ar, 193W, 60V, 30sec 
NiFe20: 25sccm Ar, 283W, 60V, 33sec 
Ta50: 50sccm Ar, 156W, 60V, 175sec 
The film composition was confirmed by Auger electron spectroscopy (AES) thin film 
elemental depth profiling, as shown in Figure 3.2. In AES depth profiling, the 
concentration of each element in the GMR stack basically follows the stack deposition 
sequence. The Ta layer serves as a seed layer of the stack. An antiferromagnetic layer 
Ir0.8Mn0.2 layer is used to pin the pinned magnetic Co0.9Fe0.1 layer. The free layer consists 
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of Co0.9Fe0.1 and Ni0.82Fe0.12 bi-layers, which is very sensitive to the external magnetic 
field. During stack deposition, there is an external magnetic field applied along the main 
flat of the silicon substrate. Figure 3.3 shows the direction of the induced magnetic 
anisotropy, which defines the easy axis of free layer on wafer level.  
After the deposition, the GMR wafer was post-annealed under 200 degree C for 30 
minutes, where the easy axis of pinned layer is defined. Figure 3.4 shows the hysteresis 
loop of the wafer level GMR stack after annealing, which is measured along the hard axis 
direction. As shown in the figure, the wafer level GMR stack shows an easy axis loop of 
the hysteresis loop, with ~350 Oe exchange bias field of the pinned layer and ~15 Oe 
coecivity field of the free layer. Figure 3.4 demonstrates that, on wafer level, the GMR 
stack has around 2.42% magnetoresistive ratio (MR) on hard axis direction, and the 
sensor sensitivity is around 0.04622 ohm/Oe. On the other hand, Figure 3.5 shows the 
hysteresis loop and transfer curve of the wafer level GMR stack measured along the easy 
axis direction. Both hysteresis loop and transfer curve show a hard axis behavior. From 
the two set of hysteresis loops and transfer curves, it is suggested that the magnetization 
of free layer aligns with that of pinned layer after annealing, which is possibly due to 
orange peel coupling
73
. 
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Figure 3.1 Schematic showing of GMR thin film stack 
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Figure 3.2 Auger electron spectroscopy thin film elemental depth profiling of GMR 
stack 
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Figure 3.3 Induced magnetic anisotropy configuration on wafer during GMR stack 
deposition 
 
Figure 3.4 Magnetic properties of wafer level GMR stack, measured along the hard 
axis 
a) Hysteresis loop 
b) Transfer curve 
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Figure 3.5 Magnetic properties of wafer level GMR stack, measured along the easy 
axis 
a) Hysterisis loop 
b) Transfer curve 
3.3 Microfabrication of GMR biosensor  
After thin film deposition, GMR wafer goes through microfabrication process. Figure 
3.6 demonstrates the main GMR biosensor patterning processes. At first, the shape and 
dimension of the GMR sensor is defined through photoresist by photo lithography. 
Secondly, using ion milling, the pattern is transferred to GMR thin film stack to form 
individual GMR sensor with same size. Then the electrode is deposited to form the 
electrical contact, using E-beam deposition and lift-off process. After that, by using the 
same techniques as electrode deposition, a thick silicon dioxide layer is formed on the 
whole wafer, except the active sensing area of GMR biosensor. The purpose is to provide 
good insulation during the test because most of the GMR biosensing is operated in 
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solution. At last, a thin layer of silicon dioxide is deposited on top of the active sensing 
area, which will be utilized as a biofunctionazation layer to bind different kinds of 
biomolecules. 
   
Figure 3.6 Schematic showing of GMR biosensor patterning process. 
3.3.1 Wafer layout mask design 
A wafer mask is typically used to define desired feature on the substrate in patterning 
process. For example, the geometries of GMR biosensor element, electric lead and 
protection layer are defined through mask in microfabrication process. Therefore, 
multilayer wafer layout masks need to be designed before the microfabrication of sensor 
chip. In biosensor chip mask design, one should consider the overall picture of patterning 
process, testing scheme and packaging method, particularly the way to accommodate 
biological sample for testing.  
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Figure 3.7 Mask design of hysteresis sensor 
a) Die layout 
b) Zoom in view of sensor definition  
 
Figure 3.8 Mask design of linear GMR sensor 
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3.3.2 Lithography 
As discussed above, the first step of patterning is to transfer device pattern onto the 
GMR stack wafer, where lithography technique is typically employed. What lithography 
does is to put down a photoresist, which has the same shape and dimension as what one 
defines in the mask design, onto the target substrate. There are two major lithography 
techniques: 1) photo-lithography; 2) e-beam lithography. Photo-lithography is relatively 
simpler and easier process, compared with e-beam lithography. However, e-beam 
lithography has much higher resolution, which ranges from submicron to tens of 
nanometers, than that of photo-lithography. Therefore, depending on the critical 
dimension of device, different lithography technique will be employed.  
In this work, both photo and e-beam lithography are used. For regular hysteresis and 
linear sensor, as shown in Figure 3.9, the physical dimensions are both in tens of 
micrometers to several micrometers range. Therefore, photo-lithography is utilized to 
transfer device pattern onto the sensor wafer. Typically, photo-lithography includes the 
following steps: a) substrate preparation; b) photoresist coating; c) soft-bake; c) exposure; 
d) develop; e) post-bake. The wafer was first prepared by being cleaned and pre-baked at 
a certain temperature, which removes contamination and moisture in order to improve 
adhesion. Then the photoresist is spin coated onto the wafer, followed by a soft-bake to 
remove the solvent of the photoresist. Next step is to exposure the photoresist under UV 
light, with the photomask over the wafer to transfer pattern. After that, the wafer, together 
Chapter 3 Sensor Fabrication and Measurement 
38 
 
with the photoresist after exposure, is submerged into developer. Depending on the type 
of photoresist (positive or negative), the developer would resolve the photoresist with UV 
exposure or without UV exposure. A post-bake process is also typically required to 
harden the photoresist and further improve adhesion to wafer after developing. The 
process for e-beam lithography is similar to that of photolithography. The major 
difference is on exposure step. Other than UV light exposure, e-beam lithography utilize 
electron beam to expose photoresist. Since the spot size of electron beam can be 
controlled to be very small, down to nanometer range, the resolution of e-beam 
lithography is capable of achieving the same pattern transfer on the same range. 
 
Figure 3.9 Mask designs of two types of sensor elements:  
a) hysteresis sensor with 80 µm × 40 µm dimension 
b) linear sensor with 100 µm × 2 µm dimension 
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3.3.3 Ion milling 
Photolithography or e-beam lithography only transfers the designed pattern onto 
photoresist. To transfer the designed pattern to onto the GMR thin film wafer, ion mill is 
needed to etch off the unneeded portion of thin film wafer. Ion milling is a dry etching 
technique. In ion milling chamber, argon atoms are bombardment by electrons 
collectively, which are confined by a magnetic field in the chamber. The ion gas which is 
formed from bombardment is then accelerated by an electric field and guided towards the 
etching target. The final step is to use ion gas to bombard the etching target and knock 
out the unwanted atoms. Since ion milling is a physical bombardment process, both metal 
and insulation layer can be etched through ion milling. On the other hand, the etching 
selectivity is not as good as wet etching techniques. In addition, the heat generated in the 
bombardment process and the re-deposition of etching material, are also challenges to ion 
milling technique, which would be addressed in the ion milling process discussed later. 
Nevertheless, ion milling is still widely used in different application, such as the 
fabrication of magnetic reader, microelectronic circuit and magnetic sensor.  
In GMR sensor fabrication, ion milling is utilized to etch the GMR thin film wafer 
with pattern photoresist. Due to the poor selectivity of ion milling, photoresist acts as a 
hard mask to process the sensor area. To avoid over etching, a reference thin film 
structure, which is deposited on a transparent plastic substrate, is placed besides the wafer 
to monitor the etching process. During the etching process, the ion beam is on and off for 
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every three minutes alternatively, to avoid the overheating of photoresist. The ion beam 
incident angle starts from 10 degree first. When the etching is almost finished, the ion 
beam incident angle is changed to 70 degree to remove the re-deposition on the sidewall 
of the sensor stack.  
After the ion milling, the photoresist needs to be removed by photoresist remover. The 
photoresist through ion milling process is typically hard to remove, due to the heating 
process during ion milling. Sometimes, a high temperature bath with photoresist remover 
is preferred to completely stripe off the resist. 
3.3.4 Electrical lead deposition 
After sensor pattern definition, electrical leads are deposited to form electric 
connection between sensor and external circuit. A standard bi-layer lift-off process and 
ion beam deposition are the major two processes for electric lead deposition.  As shown 
in Figure 3.10, the lift-off process starts with the spin coating of bilayer photoresist, SF-5 
and 1813. Then the bilayer photoresist is exposed and developed to the pattern of electric 
lead. Only electric lead area is not covered with bilayer photoresist. Next, the trilayer of 
Ta/Au/Ta are deposited through ion beam deposition, where Au is selected due to good 
conductivity and Ta is used as an adhesive layer for Au deposition. Subsequently, the 
bilayer photoresist is removed, together with the Ta/Au/Ta deposited on top of the bilayer 
photoresist.  
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Figure 3.10 Lift-off process for electric lead deposition 
3.3.5 Insulation layer deposition 
Since the biodetection usually occurs in liquid environment, the insulation of electric 
lead and sensor is important to avoid electric breakdown of biosensing chip. As shown in 
Figure 3.11, a silicon oxide with around one micrometer thickness is used as the isolation 
layer. The silicon oxide is deposited through e-beam evaporator onto the whole wafer. 
And the sensor area is exposed through lift-off process. During this process, the reference 
sensor would be cover by the thick insolation layer, so that it would not be affected by the 
magnetic signal from magnetic labels.  
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3.3.6 Biofunctionization layer deposition 
In the last fabrication process, biofunctionization layer is deposited on to the sensor. 
The purpose for biofunctionization layer is for bonding specific biomolecules, such as 
DNAs or antibodies, onto the sensor surface. Both Au and thin silicon oxide can be used 
as biofunctionization layer, where Au is used for DNA hybridization and silicon oxide is 
used to bond with antibodies. The thickness of biofunctionization layer is preferred to be 
as thin as possible in order to obtain better magnetic signal. 
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Figure 3.11 Lift-off process for isolation layer deposition 
3.4 GMR biosensor measurement 
3.4.1 DC method  
The magnetoresistance of GMR sensor was measured using a four-probe working 
station. A model Keithely 2400 sourcemeter was used to measure the resistance of the 
GMR sensor by four wire configuration. The sensing current which runs through the 
GMR sensor is 1mA, while the voltage of the GMR sensor was monitored by the 
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Keithely 2400 sourcemeter at the same time. An external magnetic field generated by an 
electromagnetic coil was applied in plane to change the magnetization direction of the 
free layer. The second function of the external magnetic field is to polarize the magnetic 
nanoparticles on the GMR sensor which could generate the stray magnetic field for 
sensing. A self-coded labview program (National instruments, USA) was used to control 
the measurement system by a computer. The typical transfer curve of GMR sensor is 
shown in Figure 2.2.  
3.4.2 AC method  
Although DC method is easy and flexible to set up, it has some drawbacks, such as 
incompatibility of real time detection and high 1/f noise. AC detection, on the other hand, 
is more flexible to integrate with microprocessor and processing circuit for mobile 
device.  
1/f noise in magnetic sensor originates from both nonmagnetic part and magnetic part. 
Nonmagnetic part of 1/f noise is from contact noise, while the magnetic part is due to the 
magnetic fluctuation in the sensor resulting from thermal noise. To address this issue, de 
Boer et al. proposed mixing frequency method in 2007
26
. The main idea is try to move 
the detection frequency away from low frequency region, where 1/f noise is dominant. 
The most straightforward way is to run a high frequency AC current through sensor, so 
that the detection frequency of sensing signal is the AC current frequency. However, it 
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results in a crosstalk signal at the AC current frequency, which is in orders of magnitude 
higher than the sensing signal. The solution is then to apply an AC magnetic field with a 
frequency different from AC current frequency. Therefore, the GMR sensing signal can 
be expressed by: 
                       
                                              
                              
 
 
                     
 
 
                     
where    is the DC part of sensor resistance,     is the variable part of the sensor 
resistance with magnetic field,    is the amplitude of AC current,    is the frequency of 
AC current and    is the frequency of AC magnetic field. As shown in Figure 3.12, 
modulation signal (side tones) is the signal without the crosstalk interference. By using a 
high pass or band pass filter, 1/f noise could then be removed. 
However, in mixing frequency method, the signal analog resolution is defined by the 
resolution of analog to digital convertor (ADC). As shown in Figure 3.12, the overall 
sensing signal is dominated by excitation current signal (carrier tone), while the side 
tones are typically a few percentages of carrier tones (MR ratio). Therefore, carrier tone 
suppression is the key to improve signal analog resolution. Traditionally, a wheatstone 
bridge would be employed to suppress the carrier, combining the reference sensor. 
However, since the resistance of sensors in an array could be varied, the wheatstone 
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bridge could not suppress carrier tone completely. We propose an adaptive referencing 
scheme, as shown in Figure 3.13. The carrier tone of each sensor would be obtained and 
suppressed by a programmable reference signal, whose amplitude and phase is the same 
as the carrier tone of the original sensor. Data acquisition card (NI USB-6289) is used for 
both tone detection and reference signal generation. 
 
Figure 3.12 frequency domain of mixing frequency method 
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Figure 3.13 Schematic drawing of adaptive referencing scheme 
 
. 
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 Application of GMR Magnetic Biosensing Chapter 4
System 
4.1 Zeptomole sensitivity demonstration of interleukin 6 detection 
4.1.1 Introduction 
Longitudinally monitoring the changes of protein biomarkers (generally < pmol)
74 
is 
expected to help design medical treatment for specific individuals
15
 and detect chronic 
diseases in their early stage, which is critical to achieve successful personalized medicine 
and control of chronic diseases.
1
 This requires a highly sensitive detecting system that is 
of low-cost, easy to use, does not require expensive instruments, and preferentially 
compatible with current electronic technologies. Since the late 1990s, 
magnetoelectronics,
75-77
 including GMR sensor,
27
 has emerged as one promising platform 
to meet such requirements.
63,65,67,78-80
 In principle, a GMR sensor would detect magnetic 
stray fields resulted from magnetic labels on the sensor surface (Scheme 1). Several 
studies have demonstrated the usage of magnetic biosensors to detect biomolecules with 
relatively large particle labels (> 250nm).
67,69,78-82
 The high mass and size of the label in 
relation to biomolecules to be tethered is expected to interfere with the natural 
biomolecule movement, recognition, and binding, which would be less serious with 
small-sized magnetic nanoparticles. However, magnetic nanoparticles as detectable labels 
acquire a smaller magnetic moment than the larger ones, requiring more sensitive sensors 
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and measurement systems. Although the detection of tens of 16 nm iron oxide 
nanoparticles by direct placement on GMR sensor surface was demonstrated,
83
 usefulness 
in real biological system is not studied. Therefore, use of small magnetic nanoparticles 
for sensitive detection and quantification of biomolecule are yet to be realized.
67,78-80
 
In this section, the development of a highly sensitive detection system based on a 
GMR sensor and 12.8nm high moment cubic FeCo nanoparticles is reported, which 
linearly detects 600 - 4500 copies of streptavidin based on biotin-streptavidin interaction 
(Figure 4.1). The feasibility of this detecting system for real biological applications is 
demonstrated, with the example of the linear detection of human interleukin 6 (IL-6, a 
potential lung cancer biomarker) through a sandwich-based principle. These results have 
been published as “A Detection System Based on Giant Magnetoresistive Sensors and 
High-Moment Magnetic Nanoparticles Demonstrates Zeptomole Sensitivity: Potential for 
Personalized Medicine”, Srinivasan, B. et al. Angewandte Chemie International Edition 
48, 2764-2767, (2009). 
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Figure 4.1 GMR sensor for detection of molecular recognition 
4.1.2 GMR sensor fabrication and surface modification 
A multilayer GMR structure of Ta (5nm) /Ir0.8Mn0.2 (10nm) /Co0.9Fe0.1 (2.5nm) /Cu 
(3.3nm) /Co0.9Fe0.1 (1nm) /Ni0.82Fe0.12 (2nm) /Ta (5nm) was deposited on thermal oxide 
silicon wafer using a six-target Shamrock sputtering system. After the deposition of 
GMR multilayer structures, a layer of photoresist 1813 was spin-coated on the wafer 
using Brewer CEE resists spinner 100. Then the wafer was exposed through a mask 
which defines the GMR sensor shape using a Karl Suss mask aligner for 5.5 seconds. 
After the development of photoresist 1813, the wafer was ion milled into a rectangle 
shape at an angle of 60 degree and 70 degree
 
in order to obtain a sharp edge. After the 
removal of the photoresist 1813, a total 210nm Ta/Cu/Ta multilayer was deposited on the 
wafer by the shamrock sputtering system. This multilayer structure was patterned by lift-
off process and used as the electrodes of the GMR sensors. In order to obtain a proper 
surface for bio-modification, an 11.4nm SiO2 layer was deposited and patterned on the 
GMR sensor area using a lift-off process. The rest of the wafer except the electrode area 
was passivated by 1 µm thick silicon dioxide. Finally, the wafer was post annealed at 
280ºC for 40 minutes under 4000 Oe magnetic field in order to pin the fixed magnetic 
layer. Figure 4.2 shows a scanning electron microscope (SEM) image of the GMR sensor 
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with a lateral dimension of 80 µm x 40 µm after the patterning. GMR sensor chip design 
layout is shown in Figure 4.3. 
GMR sensor surface was sequentially modified first with 3-
aminopropyltriethoxysilane (APTES) followed by Chromalink® biotin (Figure 4.4). 
Chromalink biotin succinimidyl ester was chosen over biotin succinimidyl ester for 
biotinylation modification, because the former has a chromophoric group for 
quantification purposes. 
 
Figure 4.2 SEM image of GMR sensor 
Chapter 4 Application of GMR Magnetic Biosensing System 
52 
 
 
Figure 4.3 GMR sensor chip design layout. 
 
Figure 4.4 Illustration of GMR sensor surface modification 
4.1.3 Estimation of the number of FeCo nanoparticles: 
Estimation of FeCo nanoparticle concentration in a dispersion of an unknown 
concentration was determined by completely digesting them in hydrochloric acid in the 
presence of oxidant like hydrogen peroxide to convert Fe to Fe(III) and measuring 
absorbance at 340nm. A known quantity of FeCo materials (50-100mg) was taken in a 
10ml vial. To this, 1ml of 30% v/v HCl and 1ml of 30% hydrogen peroxide were added. 
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The reaction mass gradually turns greenish brown and finally brown in color. The 
reaction is exothermic and starts boiling on its own and hence intermittent cooling may 
be needed to control the reaction. The reaction mass was allowed to stand for 6h at room 
temperature. After that, it was made up to 25ml in volume using DI water. Using this 
stock, 0.008M solution was made in a 50ml SMF. From this, serial dilution was made to 
obtain various concentrations. Absorbance was measured at 340 nm using a 96 well plate 
reader. A standard calibration curve was established (Figure 4.5). 
FeCo nanoparticles were deposited on PEG coated glass slides during the preparation 
process. Then the nanoparticles were washed off from the glass slides into a vial using DI 
water and made up to 3ml at a concentration approximately 100-150µg/ml in DI water 
(based on density calculations using TEM image). The nanoparticles in 250µL solution 
were collected by an external magnet field. To these particles, 100µL of 30% HCl and 
100µL of hydrogen peroxide were added carefully. Reaction mass was allowed to stand 
for 6h. After that, the final volume was made up to 300µL.  Absorbance at 340 nm was 
measured. Two more experiments were carried out similarly. Based on absorbance, the 
concentration of FeCo was calculated using the standard curve.  Results showed that 
concentration of our initial stock is 87.324±0.599 µg/ml. 
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Figure 4.5 Standard calibration curve for FeCo estimation 
Absorbance at 340 
(nm) 
Quantity of FeCo NPs in stock (µg/ml) 
0.255 ± 0.002 87.1 ± 0.5 
Table 4-1 FeCo estimation (mean ± SD; n=3) 
4.1.4 FeCo nanoparticle surface modifications 
FeCo nanoparticles were first modified with amino groups on the surface by using 
APTES (Figure 4.6), which resulted in ~ 660 APTES molecules on each nanoparticle. 
APTES modified nanoparticles were subjected to streptavidin-AF488 modification using 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) coupling chemistry. It is 
estimated that each NP is modified by 1.3 streptavidin-AF488 molecules. There is no 
significant non-specific binding of streptavidin to the magnetic nanoparticles. These data 
suggest that most particles are likely to be modified by 1 copy of streptavidin molecule. 
TEM images of APTES modified and streptavidin modified NPs were shown in Figure 
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4.7, demonstrating no significant particle aggregation. This is again critical for 
quantification of biomolecules, which is based on the magnitude of magnetic signals 
from nanoparticles 
 
Figure 4.6 Illustration of nanoparticle modification 
 
Figure 4.7 TEM images of FeCo nanoparticles modified by a) APTES and b) 
streptavidin-AF488. 
To demonstrate the incorporation of ATPES on FeCo nanoparticles, aqueous solution 
of bare FeCo nanoparticles and APTES modified FeCo nanoparticles were applied on 
carbon film coated copper grids. Energy dispersive X-ray spectra (EDX) was taken on 
field emission gun transmission electron microscope (FEI Tecnai G2 30). Strong signal 
of Si in the ATPES modified FeCo NPs sample confirmed the successful modification 
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(Figure 4.8) while the very weak signal of Si detected in bare FeCo NPs sample was 
within random error range (Figure 4.9). 
4.1.5 Biotin-Streptavidin detection 
To explore the sensitivity of this GMR sensor- and magnetic nanoparticle-based 
detecting system, varied quantities of streptavidin-AF488 modified magnetic 
nanoparticles were applied onto the surface of GMR sensor modified by Chromalink® 
biotin. After thorough wash to remove the potentially unbound streptavidin, the magnetic 
signals from the magnetic nanoparticles specifically retained on the GMR sensor through 
biotin-streptavidin interactions were measured by the GMR sensor. 
 
 
Figure 4.8 TEM-EDX spectra of bare FeCo NPs dispersion in water 
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Figure 4.9 TEM-EDX spectra of APTES modified FeCo NPs dispersion in water 
As shown in Figure 4.10 (a), the GMR sensor detected signals from as low as 600 
copies (< 10
-21
 mol, zeptomol) of streptavidin, the sensitivity of which is expected to 
detect all potential biomarkers from 10 nanoliter or less body fluid. More importantly, 
there is a linear dose-response relationship of the amount of streptavidin applied and the 
magnetic signals detected by the GMR sensors. Such a dynamic range of linearity 
outperforms most other GMR based detecting systems reported to date, making accurate 
quantification possible. The signal detected on biotin modified GMR sensor is introduced 
through the biotin-streptavidin interaction as the control sensors with no biotin 
modification detected no resistance changes under the identical experimental conditions. 
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Figure 4.10 GMR sensor signal of streptavidin and IL-6 
a) Resistance change for different amounts of streptavidin molecules on the GMR 
sensor. Blue: GMR sensors with surface modified by biotin. Gray: GMR sensors with 
no biotin modification. b) Resistance change detected by sensors for different amounts 
of IL-6 molecules modified on the sensors using a sandwich structure. The same 
amount of capture antibody and detection antibody-modified magnetic nanoparticles 
was applied to each sensor with varied numbers of IL-6 molecules. Yellow: IL-6 
modified GMR sensors. Gray: GMR sensors with no IL-6 modification. 
4.1.6 Human interleukin-6 detection 
To further explore the practical usage of this GMR sensor-magnetic nanoparticle-
based detecting system, we evaluate the potential of this system to detect human 
interleukin-6 (IL-6, a potential serum biomarker for lung cancer) using a sandwich 
approach, which follows the same principle of Enzyme-Linked ImmunoSorbent assay 
(ELISA). Monoclonal anti-human IL-6 antibody (capture) was covalently attached to 
APTES modified GMR sensor using EDC coupling chemistry. Recombinant human IL-6 
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is allowed to bind to capture antibody on the GMR sensor surfaces. Polyclonal anti-
human IL-6 antibody (detection) was magnetically labeled with APTES modified FeCo 
nanoparticles through covalent linkage in a 1.19:1 fashion. Magnetic particle labeled 
detection antibody was allowed to bind IL-6 bound sensor surface. 
As shown in Figure 4.10 (b), the GMR sensor detected signals from as low as 
2.08x10
6
 IL-6 molecules. The sensitivity for IL-6 ELISA assay (R&D, D6050) is 
2.79x10
7
 IL-6 molecules, which is 13 times less sensitive than our un-optimized GMR 
sensor- and magnetic nanoparticle detecting system. More importantly, there is a linear 
dose-response relationship between the amount of IL-6 applied and the magnetic signals 
detected by the detecting system. Currently work is undertaken in our laboratory to 
optimize the sandwich assay conditions to improve the sensitivity and dynamic detecting 
range. 
4.1.7 Conclusion 
In conclusion, we have established a GMR sensor- and high-moment magnetic 
nanoparticle-based detecting system that, for the first time, detects as few as 600 copies 
of streptavidin, which is modified by 12.8nm cubic FeCo nanoparticle in a 1:1 ratio. We 
also demonstrated that this detecting system can adopt the principle of ELISA assay with 
increased sensitivity. GMR and magnetic nanoparticle based detecting system is expected 
to be applicable to many other biological systems for detection and quantification of 
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various biomolecules. The high sensitivity of this detecting system open new avenues for 
the detection of biomolecules involved in the etiology of various diseases, especially the 
chronic ones, such as cancer, which is now under investigation. It can also be used to 
monitor residual disease and disease reoccurrence. Most importantly, because of the 
magnetic/electric nature of this detecting system, we expect that this detecting system 
will help the realization of point-of-care. 
4.2 Competition-based nanomagnetic assay for low-abundance protein biomarker 
quantification in unprocessed human sera 
4.2.1 Introduction 
Traditional technologies for disease biomarker detection are enzyme-linked 
immunosorbent assays (ELISA)
84,85
, Western Blotting, immunohistochemistry, DNA 
based genomics, and mass spectrometry based proteomics and metabolomics
86
. With no 
exception, these approaches have intrinsic common limitations, including expensive 
equipment, long processing time, extensive professional training, and low signal-to-noise 
ratio
22
. Methods that can rapidly and specifically quantify disease biomarkers from 
human unprocessed body fluids with low cost are expected to greatly facilitate disease 
biomarker validation and disease early detection. Sensing based on the combination of 
GMR sensors and magnetic nanoparticles has attracted much attention as a promising 
alternative
23-28,56,57,63,64,67,68,72,87-91
. Nevertheless, most GMR biosensor application has 
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been confined to proof of detecting concept
64,67,68,88
, model studies
89,90
, or detection of 
spiked biomolecules, the concentration of which generally are orders of magnitude higher 
than the physiological relevant ones
24,72,91
, mainly because its theoretical sensitivity has 
not been achieved under physiological conditions. 
This study reports the first realization of specific, accurate, and rapid quantification of 
interleukin-6 (IL-6), a low-abundance protein and a potential cancer biomarker
92
, in 
unprocessed human sera, by employing our novel near 0-degree GMR sensor with our 
uniform high-moment magnetic nanoparticles and minimizing the detecting distance 
between nanoparticles and GMR sensing. Such integration led to significant increase of 
detecting sensitivity and accuracy. The near 0-degree design of the GMR sensor also 
eliminates the need of a high magnetic field for detection, which open the opportunity for 
portable device. Our platform therefore has a significant impact for magnetic sensor-
based biomolecule detection with the potential to develop a lab-on-chip device, practical 
for frequent biomarker detection and monitoring. These results have been published as 
“Nanomagnetic Competition Assay for Low-Abundance Protein Biomarker 
Quantification in Unprocessed Human Sera”, Li, Y. et al. Journal of the American 
Chemical Society 132, 4388-4392, (2010).  
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4.2.2 Three-layer and two-layer approaches 
The methodology of GMR biosensor and magnetic nanoparticle-based family medical 
device, in case of protein detection, includes two basic detection schemes: three-layer 
approach and two-layer approach. As shown in Figure 4.11 (A), three-layer approach 
contains the following steps: the GMR biosensors are first functionalized with capture 
antibodies specific to the analyte; then analyte are applied onto the GMR biosensor and 
followed by the magnetic nanoparticle labeled (MNL) detection antibodies; finally, the 
analyte are sandwiched by the capture antibody and MNL detection antibody. By 
detecting the bond magnetic nanoparticles by GMR biosensor, the captured analyte can 
be quantified. Alternatively, two-layer approach, as illustrated in  Figure 4.11 (B), only 
requires the direct application of MNL analyte onto the capture antibody modified sensor. 
Although based on different modification steps, these two approaches share the same 
magnetic nanoparticle detection principle. Since the magnetic nanoparticle used for 
labeling is superparamagnetic, the magnetic dipole field Hdip of the superparamagnetic 
nanoparticle is given: 
35
)(3
rr
mrrm
Hdip 

                                               
where r is the space vector pointing from the center of superparamagnetic nanoparticle 
to the point where the field is measured, m=VχHa is the magnetic moment of the 
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superparamagnetic nanoparticle under the applied field Ha, V is the volume of the 
superparamagnetic nanoparticle and χ is the susceptibility of the superparamagnetic 
nanoparticle. Hence, the effective magnetic field Heff on the sensor considering the dipole 
field from the nanoparticles is Heff = Ha-Hdip. Because the resistance of GMR biosensor 
responses easily to the in-plane magnetic field, the magnetic dipole field from the 
nanoparticle could be picked up by the GMR biosensor, which is represented by the 
change of sensor resistance after the magnetic nanoparticle binds to the sensor surface. 
From equation 5.1, it is clear that the detection signal is highly sensitive to the distance 
between the magnetic nanoparticle and the GMR biosensor. Therefore, the sensitivity of 
this system is expected to be improved by adopting two-layer approach since the 
magnetic nanoparticle is closer to the GMR biosensor than that in three-layer case. 
Since the dipole field is much smaller than that with the applied field, we can assume a 
linear relationship between the resistance R and the effective magnetic field: 
 
where C is a coefficient. For a bare GMR sensor, the effective magnetic field on the 
sensor is just the applied field. So the resistance of the sensor R0 in this case is: 
 
After the nanoparticle attachment, the effective magnetic field on the sensor 
considering he dipole field from the nanoparticles is Heff = Ha-Hdip. Hence, the resistance 
of the sensor R1 is: 
 
 
effHCR 
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1
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eff
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Therefore, the sensing signal S is defined as the resistance different with and without 
nanoparticle attachment: 
 
 
 
The sensitivity improvement is defined as the ratio of sensing signals in two-layer case 
S
b
 and three-layer case S
s
: 
 
 
 
 
 
 
 
 
 
where r
s
 and r
b
 is the distance between the center of magnetic nanoparticle and the sensor 
surface in three-layer and two-layer structure, respectively. Assuming the capture 
antibody, IL-6 and detection antibody vary size from 3nm to 30nm
93
, then we can 
calculate the dynamic range of sensitivity improvement. For the maximum sensitivity 
improvement, we consider: a three-layer structure of 3nm capture antibody, 3nm IL-6 and 
30nm detection antibody; a two-layer structure of 3nm capture antibody and 3nm IL-6. 
For minimum sensitivity improvement, we consider: a three-layer structure of 30 nm 
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capture antibody, 30nm IL-6 and 30nm detection antibody; a two-layer structure of 30nm 
capture antibody and 30nm IL-6. Therefore, the dynamic range of the sensitivity 
improvement is from 3.4 up to 39.3. 
 Currently, most GMR detection of protein-based biomolecules in publications 
employs a three-layer (sandwich)-based approach, which compromises the detection 
sensitivity to the whole system. To demonstrate the sensitivity improvement 
experimentally, we explored the sensitivity of this system for human IL-6 detection, a 
potential serum biomarker for lung cancer, employing both three-layer and two-layer 
approaches. In this paper, the binding efficiency of capture antibody, detection antibody 
and IL-6 were optimized in order to maximize the sensor sensitivity. As shown in Figure 
4.12 as low as 20.76 pM
 
IL-6 molecules were detected based on three-layer approach, 
while two-layer approach increases the sensitivity of this system up to the detection of 
373 fM MNL IL-6 molecules, which is around 50 times more sensitive to the three-layer 
approach. The sensitivity increase in two-layer case is mainly due to smaller distance 
between the magnetic nanoparticles and the GMR biosensor. 
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Figure 4.11 Two GMR sensor and magnetic nanoparticle-based biomolecule detection 
schemes.  
(A) Three-layer (Sandwich) approach: the GMR sensors are first functionalized with 
capture antibodies. The analyte binds to the capture antibody. Subsequently, detection 
antibodies labeled with magnetic nanoparticles are then applied and bind to the 
captured analyte. (B) Two-layer approach: after the functionalization of the GMR 
sensor with capture antibodies, the magnetic nanoparticle modified analyte is directly 
applied and captured on the GMR biosensors. (C) GMR biosensor working principle. 
The GMR biosensor can detect the dipole field generated by the magnetic 
nanoparticles captured on the sensor surface, which is sensitive to distance. 
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Figure 4.12 Sensitivity comparison between three-layer and two-layer approaches. 
Dose response curves of three-layer approach and two-layer approach are shown. For 
three-layer approach, the same amount of detection antibody modified FeCo magnetic 
nanoparticles were applied to each sensor with different amounts of unlabeledIL-6 
molecules. For two-layer approach, different amount of FeCo MNL IL-6 molecules 
were applied on each sensor. 
4.2.3 Two-layer Based Competition Detection Scheme 
To test unprocessed real biological sample directly, we propose two-layer based 
competition detection scheme. Although high sensitivity can be achieved based on two-
layer approach as discussed above, it requires labeling target analyte with magnetic 
nanoparticle in the testing sample, which decreases the feasibility of the GMR biosensing 
system. The competition detection scheme (Figure 4.13) enables the quantification of 
unlabeled analyte through the detection of MNL analyte. In addition, as shown in Figure 
4.14, non-competition based detection scheme may result in non-monotonic solution, if 
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the capture antibody or MNL detection antibody is not sufficient to the analyte. Therefore, 
an estimation of the analyte would be preferred to avoid such situation. However, in the 
case of competition detection scheme, the monotonic of detection result can always be 
achieved due to the nature of competition dose response curve (Figure 4.15). Following 
the two-layer approach, the MNL analyte are mixed with unlabeled analyte in the real 
sample and the mixture is applied on the same capture antibody functionalized GMR 
biosensor. The MNL and unlabeled analyte will compete with each other for limit amount 
of binding sites of capture antibodies with different efficiencies. As proof of concept, we 
quantified the IL-6 molecules using the competition scheme. The mixture of 4.15 pM 
MNL IL-6 molecules and varied amounts of unlabeled IL-6 was applied on the GMR 
biosensors. Figure 4.13 (b) shows the dose response curve of the competition detection 
scheme, which provides a large dynamic detection range from 125 fM to 41.5 pM 
unlabeled IL-6 molecules. This improvement is contributed from the fact: the less 
unlabeled IL-6 in the mixture, the more MNL IL-6 binding to the GMR biosensor, 
generating more magnetic signal for enhanced signal-to-noise ratio. 
4.2.4 Unprocessed Human Serum Sample Quantification 
We conducted the quantification of IL-6 molecules in real human serum samples using 
two-layer based competition detection scheme. Ten human serum samples were 
evaluated. Five of them were from healthy individuals, which were labeled as NS1 to 
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NS5. The other five were from lung cancer patients, labeled as CS1 to CS5 (Table 4-2). 
Briefly, MNL IL-6 molecules were mixed with these unprocessed human serum sample 
(4 μL) and applied onto the GMR sensor surface (MNL IL-6 at a concentration of 4.15 
pM in 4nL unprocessed human serum samples per sensor area). The concentration of IL-
6 in the human serum samples was determined by using the above established 
competition-based dose response curve (Figure 4.13). Figure 4.16 compares the levels of 
IL-6 in human sera quantified by our GMR biosensor and those by commercial ELISA 
(R&D systems). Significant amount of IL-6 can be detected and quantified by our GMR 
biosensor in all ten unprocessed serum samples, while ELISA failed to detect IL-6 in four 
of the five sera from healthy individuals, NS2-NS5. The levels of IL-6 in sera NS1, CS2-
CS5 quantified by our GMR sensor are comparable to those determined by ELISA. 
However, there is a significant discrepancy of IL-6 abundance in unprocessed serum CS1 
between the results from ELISA (2.42x10
4
 fM) and our device (1.96x10
5
 fM). We 
hypothesize that the IL-6 level in CS1 is relatively high that it is out of the linear 
detecting range of ELISA and that the result from ELISA underestimates the quantity of 
IL-6 in CS1. To test this hypothesis, serum CS1 was diluted 80 times so that the level of 
IL-6 would be within the linear detecting range of ELISA based on our GMR data. The 
diluted sample was then re-evaluated by ELISA. The ELISA result from this diluted 
measurement (1.92x10
5
 fM) agreed nicely with our GMR data (Figure 4.16, Table 4-3), 
demonstrating the accuracy and wide detecting range of our GMR biosensor-based 
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detecting system. Excitingly, the levels of IL-6 in the five sera from lung cancer patients 
are all significantly higher than those in the sera from healthy individuals, preliminarily 
supporting IL-6 as a potential lung cancer biomarker. 
 
 
Figure 4.13 Two-layer based competition detection scheme 
(A) Competition-based two-layer based detection scheme: the magnetic MNL IL-6 
and unlabeled IL-6 are applied on the capture antibody functionalized GMR biosensor 
and compete for the binding sites. (B) Two-layer based competition dose response 
curve between 4.15 pM FeCo MNL IL-6 and varied concentrations of unlabeled IL-6 
molecules. The solid curve is the non-linear dose fitting curve.  
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Figure 4.14 The non-monotonicity in three-layer detection scheme for unknown 
samples.  
In case of high concentration (A) and low concentration (B) sample, same amount of 
magnetic nanoparticles could be bond on the surface and generate same signals (C). 
(The red line is the guide for eyes) 
 
Figure 4.15 The monotonicity in two-layer based competition detection scheme for 
unknown samples.  
In case of high concentration (A) and low concentration (B) sample, the system will 
generate different signal (C). 
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Serum 
sample 
NS1 NS2 NS3 NS4 NS5 CS1 CS2 CS3 CS4 CS5 
Promedd
x 
number 
1129026
6 
1129026
8 
1129030
6 
1129059
5 
1129062
4 
1066975
2 
1120139
7 
1123061
9 
1127584
9 
1127585
2 
Cancer 
Type 
No 
cancer 
No 
cancer 
No 
cancer 
No 
cancer 
No 
cancer 
Lung Lung Lung Lung Lung 
Table 4-2 human serum samples details 
 
Figure 4.16 Comparison of IL-6 levels in human serum samples determined by ELISA 
and competition-based GMR biosensor.  
Columns: mean; bars: standard deviation (2≤n≤8); NS1-NS5 stands for human serum 
samples from five healthy individuals; CS1-CS5 stands for human serum samples 
from five lung cancer patients. Processed serum means that CS1 was diluted 80 times 
for ELISA quantification while unprocessed serum means the serum sample was 
evaluated as such. ELISA failed to detect IL-6 in NS2-5. 
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[IL-6] 
fM 
NS1 NS2 NS3 NS4 NS5 CS1 CS2 CS3 CS4 CS5 
ELISA 219 N/A[a] N/A[a] N/A[a] N/A[a] 
192140
[b] 
552 742 3928 757 
GMR 248 122 56 203 112 195981 567 597 3681 627 
[a] N/A – Not detectable by ELISA; [b] After 80-fold dilution 
Table 4-3 Comparison of IL-6 levels in human serum samples determined by ELISA 
and GMR biosensor. 
4.2.5 Detection Specificity, Time and Reproducibility 
We then performed a series of experiments to examine the detecting specificity of our 
device. One approach evaluating the detecting specificity of IL-6 in sera was to determine 
whether serum samples depleted of IL-6 would introduce any signals. IL-6 in serum 
samples from NS1 and CS1 were depleted by an immunoprecipitation approach. The 
depleted sera were then used in competition with MNL IL-6, following the same 
procedure. The results (Figure 4.17 (A)) demonstrate that the IL-6 depleted sera, 
irrespective of their disease state and original IL-6 level, show no competition at all 
against MNL IL-6, establishing the detecting specificity of our device to IL-6. The 
detecting specificity against other specific serum proteins of varied abundance was also 
evaluated. MNL IL-6 was mixed with either 10
6
-fold human recombinant interleukin-8 
(IL-8), human vascular endothelial growth factor (VEGF), human recombinant fatty acid 
synthase (FAS), or 10
10
-fold human albumin from serum (HAS) for competition 
detection. Again, we detected no signal changes due to the non-specific binding of these 
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other serum proteins even when they are in high excess compared to IL-6 (Figure 4.17 
(B)). 
Finally, the detection time and reproducibility of our biosensing system were 
preliminarily evaluated. The time-course binding of MNL IL-6 to GMR sensor was 
studied. As show in Figure 4.17 (C), 94% signal was achieved within 1 minute and the 
binding reached equilibrium for quantification within 5 minutes, demonstrating the 
feasibility to realize quick detection. The system also demonstrates high reproducibility 
as shown in Figure 4.17 (D) that different GMR sensors, when used to quantify 4.15 pM 
IL-6 at four different time points, produces the same results. 
4.2.6 Conclusion 
In summary, an ultra-sensitive, highly specific and reproducible, and rapid sensing 
platform with a wide detecting range has been developed. This platform consists of the 
integration of a near-0 degree GMR sensor with uniform high moment magnetic 
nanoparticle-based device and a competition-based detecting principle. The feasibility of 
this system to directly quantify IL-6 in unprocessed human serum samples in five 
minutes has been demonstrated. Although 4 μL serum was used for this analysis, only 4 
nL of the serum is indeed responsible for signal, because we have not achieved sensor 
area-specific modification that the capture-antibody modified area includes the sensor 
and its surrounding area.  The surrounding area is ~1,000 times the sensor area. Hence, 
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upon achieving sensor-specific modification, our sensor platform would require only 4 
nL of serum or it can quantify IL-6 from serum of much lower IL-6 concentration, which 
is currently under investigation. The detecting specificity of this system was rigorously 
established by demonstrating that IL-6 depleted sera introduced no signal at all. Rapid 
detection (5 min) and reproducibility were also demonstrated for this system.  Such a 
platform paves the practical way for the identification and validation of biomarkers 
involved in the etiology of various diseases. It may eventually lead to a low-cost and 
handheld medical device for early detection of chronic diseases. 
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Figure 4.17 Detecting specificity, dynamics, and reproducibility of IL-6 
(A) Resistance change in the absence or presence of IL-6 depleted serum with MNL 
IL-6 molecules. a) Control, no IL-6 depleted serum; b) IL-6 depleted serum from NS1; 
c) IL-6 depleted serum from CS1 (B) Resistance change in the presence of other 
proteins with MNL IL-6 molecules (1.25 pM MNL IL-6). a) Control, no competition; 
b) 1.25x106 pM IL-8; c) 1.25x106 pM VEGF; d) 1.25x106 pM FAS; e) 1.25x1010 
pM HAS. (C) Time course binding study. (D) Resistance change due to competition of 
unlabeled recombinant human IL-6 with MNL IL-6 molecules on the sensor surface, 
a-d) competition results from four independent experiments that were performed with 
a one-week interval between two experiments. 
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4.3 A Three-Layer Competition Based Quantification of Endoglin 
4.3.1 Introduction 
While patients with high grade prostate cancer make up only 15-20% of those with 
prostate cancer, they represent more than half of the patients who die from prostate 
cancer
94
. Early identification of patients with high grade prostate cancer is critical to 
making inroads into reducing prostate cancer related deaths
95
. While used ubiquitously to 
screen for prostate cancer, prostate specific antigen (PSA) is neither a sensitive nor a 
specific biomarker for discriminating between low grade and high grade prostate 
cancer
96
. Thus, there is an urgent need for additional biomarkers both to improve 
identification of patients with prostate cancer and to differentiate patients with low-risk 
and high-risk cancers.  
A number of urine-based markers have been investigated for the diagnosis of prostate 
cancer, including DNA, RNA and protein markers
97-99
. In a single site study among 
patients undergoing prostate biopsy, levels of urinary endoglin detected by ELISA were 
shown to distinguish between patients with prostate cancer and those without prostate 
cancer
100
. The predictive value was found to be superior to the predictive value of 
PSA
100
. Of particular interest, urinary endoglin was able to distinguish between high 
volume and low volume diseases. It remains to be determined of its diagnostic potential 
between low-grad and high-grade prostate cancer. Typically, these urinary markers are 
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detected either by ELISA or by western blotting. These techniques can have inherent 
disadvantages including the need to concentrate urine by dialysis to facilitate detection; 
these obstacles can increase cost, lead to testing errors and involve the need for 
institutional laboratory testing
97,98
. Therefore alternative technology is needed to feasibly 
detect endoglin directly from urine. 
In principle, a magnetic biosensing system uses GMR sensor to detect stray magnetic 
field resulting from magnetic labels on the sensor surface. Its application in real 
biological systems, such as unprocessed human serum and urines, has been very limited, 
potentially due to the limited biological sensitivity
23,24,27,63,64,66,67,72,82,88,90,91,101-103
. In 
previous chapter, we have discussed a new GMR sensing platform that has unique 
features improving its sensitivity – near 0º ground state for the sensor (3-fold increase in 
sensitivity) and use of high magnetic moment uniformly sized small (12.8±1.58 nm) 
cubic shaped FeCo nanoparticles
104
 (7-fold increase in sensitivity). Based on the 
detecting principle, GMR sensor sensitivity strongly depends on the distance (d) between 
the magnetic nanoparticle and the sensor surface. The magnetic signal decreases as the 
distance increases
104
. Currently, all other GMR detection of biomolecules employs a 
three-layer (sandwich) approach that has three biomolecules between GMR sensor and 
magnetic nanoparticle
23,24,27,63,64,66,67,72,88,90,91,101-103
. A two-layer competition based 
nanomagnetic assay, which reduces the detection distance by removing the detecting 
antibody between GMR sensor and magnetic nanoparticle, further improving the 
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detecting sensitivity (55-fold for IL-6)
104
, is discussed in previous chapter too.  By 
integrating these, the sensitivity has been improved by 1000-fold and we have 
demonstrated that our device can directly detect and quantify low-abundance IL-6 protein 
directly from 4µL of unprocessed serum sample
104
.  
In this section we discuss a competition magnetic bioassay (Figure 4.18), in order to 
quantify endoglin directly from unprocessed human urine samples using our GMR 
biosensing technology and to evaluate whether endoglin levels in urine have the potential 
to predict for the presence of prostate cancer and to distinguish between different grades 
of prostate cancer. These results have been published as “A Three-Layer Competition-
Based Giant Magnetoresistive Assay for Direct Quantification of Endoglin from Human 
Urine”, Srinivasan, B. et al. Analytical Chemistry 83, 2996-3002, (2011). 
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Figure 4.18 Two-layer and three-layer competition detection scheme 
A: Two-layer competition detection scheme: the GMR sensors are first functionalized 
with capture antibodies (a). Nanoparticle labeled endoglin and unlabeled endoglin 
were then mixed and applied on the sensor surface to compete for capture antibodies 
(b). B: Three-layer competition detection scheme: the GMR sensors are first 
functionalized with capture antibodies. Biotin labeled endoglin and unlabeled endoglin 
were then mixed and applied on the sensor surface to compete for capture antibodies 
(c). Subsequently, streptavidin-FeCo nanoparticle conjugates were applied for binding 
(d and e). 
4.3.2 Experimental methods 
GMR sensor and nanoparticle fabrication and magnetoresistance measurement: 
Fabrication of GMR sensor and high magnetic moment cubic FeCo nanoparticles and 
magnetoresistance measurements were carried out by following the same procedures as 
described in earlier report
72
 and Chapter 3.
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Sensor surface modification: GMR sensor surface was sequentially modified with 
(3-aminopropyl)triethoxysilane (APTES) followed by capture antibody attachment 
through 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (EDC) coupling reaction. 
After each step, the surface was thoroughly washed with water to remove unbound 
ligands, which were collected for quantification. For each step of modification, bound 
ligands were quantified using the following equation: amount of bound ligand on the 
surface = amount of total ligand added – amount of ligand recovered. 
Cubic FeCo nanoparticle surface modification: i. APTES modification: A solution 
of APTES (100 µg in 0.5mL ethanol) and ammonium hydroxide (5µl, 29%) was added to 
cubic FeCo nanoparticles (100µg) and sonicated for 4h. ii. Human recombinant endoglin 
modification: To a dispersion of FeCo nanoparticles (0.3mL, PBS buffer, pH 7.4; 30µg of 
FeCo nanoparticles), dylight 488 labeled endoglin (6.2 µL, 0.5mg/mL in PBS buffer, pH 
7.4) and EDC (10µL, 5mg/mL in PBS buffer, pH 7.4) was added and shaken overnight at 
4ºC under light-protected conditions. Endoglin to nanoparticle ratio was found to be 
1.36:1 upon quantification. iii. Streptavidin-AF488 modification: FeCo nanoparticles are 
modified with streptavidin-AF488 in a ratio of 1:1.3 according to our previously 
published procedure
72
. 
Two-layer competition assay for human endoglin in urine samples: A 4 µL 
mixture of urine sample (4 nL per sensor area) and high magnetic moment FeCo 
nanoparticle labeled endoglin (1.66 x10
-20
 mol per sensor area, 4.15 pM, 
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nanoparticle/endoglin = 1.357) was applied to compete for capture antibody (1.66 x10
-20
 
mol per sensor area) on the GMR sensor surface for 10 min at 4ºC. Resistance change of 
the GMR sensor was measured. 
Three-layer competition assay for human endoglin in urine samples: A 20µL 
mixture of urine sample (20 nL per sensor area) and endoglin-biotin20 (1.66 x10
-20
 mol 
per sensor area, 0.83 pM) was applied to compete for capture antibody (1.66 x10
-20
 mol 
per sensor area) on the GMR sensor surface for 30 min at 4ºC. Then streptavidin-FeCo 
nanoparticle conjugate (41.5 pM, 1.66x10
-19
 mole streptavidin per sensor area, 
streptavidin/nanoparticle 1.3:1) was applied for binding for 10 min at 4ºC followed by 
washing with water to remove unbound streptavidin-FeCo nanoparticle conjugates. 
Resistance change of the GMR sensor was measured. 
Three-layer competition assay dose response curve: Briefly a spiked mixture of 
endoglin-biotin20 (1.66x10
-20
 mol per sensor area, 0.83 pM) and varied concentrations of 
unlabeled endoglin in 20µL endoglin depleted urine cocktail was applied on the sensor 
surface to compete for capture antibody (1.66x10
-20
 mol per sensor area) on the sensor for 
30 min at 4ºC. Then streptavidin-FeCo nanoparticle conjugate (41.5 pM, 1.66x10
-19
 mole 
streptavidin per sensor area, streptavidin/nanoparticle 1.3:1) was applied for binding for 
10 min at 4ºC followed by washing with water to remove unbound streptavidin-FeCo 
nanoparticle conjugates. Resistance change of the GMR sensor was measured. 
Chapter 4 Application of GMR Magnetic Biosensing System 
83 
 
Total urinary protein estimation: Total urinary proteins in the urine samples were 
determined by micro pyrogallol red method using a total protein kit, (catalog number 
TP0400) purchased from Sigma Aldrich following vendor’s protocol.  
Creatinine quantification in urines: Quantitative determination of creatinine in the 
urine samples were determined by using creatinine assay kit (catalog number KGE005) 
purchased from R&D Systems, Inc., Minneapolis, USA following vendor’s protocol. 
4.3.3 Results and discussion 
Two-layer competition assay for urinary endoglin detection: Two-layer 
competition assay (Figure 4.18 (A)) was used first to detect endoglin from the urine 
(4µL) where urinary endoglin competes with high magnetic moment FeCo nanoparticle 
labeled endoglin (1.66x10
-20
 mol per sensor area, 4.15 pM, nanoparticle/endoglin = 
1.357) for capture antibody (1.66x10
-20
 mol per sensor area) on the GMR sensor surface. 
Nanoparticle labeled endoglin in PBS buffer, pH 7.4 (4µL, 1.66x10
-20
 mol per sensor 
area, 4.15pM) binding to capture antibody on the sensor surface served as one control.  
The other control (for non-specific competition) uses endoglin depleted urine U1 to 
compete with high magnetic moment FeCo nanoparticle labeled endoglin (1.66x10
-20
 mol 
per sensor area,4.15pM) for capture antibody (1.66 x10
-20
 mol per sensor area) on the 
GMR sensor surface. High grade prostate cancer patient urine U1 (4µL) under this 
condition resulted in no statistical significant resistance change as a sensing signal 
compared to controls. This observation in part may be result of urinary endoglin cannot 
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effectively compete and easily displace nanoparticle labeled endoglin (if nanoparticle 
labels the endoglin at the proximity of its binding site) from the capture antibody binding 
site and/or very low competition from urinary endoglin in that sample due to low 
abundance. Hence the urine sample U1 was lyophilized and reconstituted in double 
distilled water to obtain 6.67 fold concentrated sample for testing under two-layer 
competition assay. Although the concentrated urine sample U1 showed statistically 
significant resistance change, the magnitude of resistance change is small (Figure 4.19 
(A)).  
 
Figure 4.19 Resistance changes from urine samples 
A: Resistance change due to competition of urine sample with magnetic nanoparticle 
labeled endoglin (4.15pM)  
a) control, no competing urine sample; b) urine U1 from a high grade prostate cancer 
patient; c) 6.66-fold concentrated urine U1 from a high grade prostate cancer patient;  
d) endoglin depleted urine U1 from a high grade prostate cancer patient.  
B: Resistance change due to competition of  6.66 fold concentrated urine samples with 
magnetic nanoparticle labeled endoglin (4.15pM) a) control, no competing urine; b) 
U1; c) U2; d) U3; e) U6; f) U7; g) U8; h) U11; i) U12; j) U13.  
C: Average resistance change caused by i) three high grade prostate cancer urines (U1-
U3); ii) three low grade prostate cancer urines (U6-U8); iii) three no prostate cancer 
urines (U11-U13); a) control, no competing urine. 
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Using this method, three samples from each group (urines U1-U3 from patients who 
are biopsy positive for high grade prostate cancer; U6-U8 low grade prostate cancer; and 
U11-U13 from individuals who are biopsy negative for cancer) were tested (Figure 4.19 
(B)). Upon signal averaging, high grade urine samples group showed statistical 
significant resistance change whereas low grade and no cancer urine samples groups did 
not showed any statistical significant resistance change compared to control. Though the 
two-layer competition assay results are encouraging, urine samples need to be 
concentrated; and low grade prostate and no cancer patients cannot be differentiated by 
endoglin levels in the urines (Figure 4.19 (C)). 
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Figure 4.20 Resistance changes upon binding to capture antibody modified (1.66x10
-20
 
mol capture antibody per sensor area) sensor surface  
a) nanoparticles harvested form one nanoparticle per endoglin reaction (4.15pM 
endoglin); b) nanoparticles harvested from two nanoparticle per endoglin reaction 
(4.15pM endoglin); c) endoglin-biotin20 (4.15pM) followed by nanoparticles harvested 
Chapter 4 Application of GMR Magnetic Biosensing System 
86 
 
from one nanoparticle per streptavidin reaction (41.5 pM streptavidin) binding; d) 
endoglin-biotin20 (4.15pM) followed by nanoparticles harvested from two nanoparticle 
per streptavidin reaction (41.5 pM streptavidin) binding. 
Two nanoparticles labeling of endoglin was sought to improve the sensitivity of this 
detection scheme as the sensing signal comes from the nanoparticle labeling.  To achieve 
one nanoparticle labeling per endoglin, we used one equivalent of nanoparticles and 1.5 
equivalents of endoglin under coupling reaction conditions. Hence for two nanoparticles 
labeling of the endoglin, we used one equivalent of nanoparticles and three equivalents of 
endoglin for reaction. When we used harvested particles from the endoglin two 
nanoparticles labeling reaction on our GMR sensor, signal improved minimally compared 
to one nanoparticle labeled endoglin binding (Figure 4.20) indicating that two 
nanoparticle cannot be attached per endoglin potentially due to comparable sizes of 
endoglin and nanoparticle and the other one equivalents of the particle remain 
unmodified which gets washed off after binding event. 
Three-layer competition assay for urinary endoglin detection: The other way to 
accomplish more than one nanoparticle per endoglin to gain assay sensitivity is to modify 
endoglin with several biotins; and biotins on the endoglin can be recognized by 
streptavidin-nanoparticle conjugates (Figure 4.18 (B)). Endoglin molecules were labeled 
with biotin using biotin N-hydroxysuccinimidyl ester coupling chemistry to have biotin 
to endoglin ratio 4, 8, 12, 16 and 20. To identify the right biotin loading per endoglin to 
bind more streptavidin, optimization experiments were done on silica wafer. Capture 
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antibodies were covalently coupled to silica wafers modified with 3-
aminopropyltriethoxysilane (APTES).  Endoglin labeled with different copies of biotin 
(4, 8, 12, 16 and 20 biotin copies per endoglin) were applied to each capture antibody 
modified wafer surfaces. Fixed amount of streptavidin-AF488 was applied to all 
endoglin-biotin bound surfaces and unbound streptavidin-488 from each spots was 
quantified. From the results, one endoglin-biotin20 (one endoglin molecule is labeled with 
20 copies of biotin molecules) was found to capture 3.2 copies of streptavidin-AF488. If 
streptavidin-nanoparticle conjugate (streptavidin/nanoparticle, 1.3:1) binds similarly as 
streptavidin-AF488 to endoglin-biotin20, then this will result in three nanoparticles per 
endoglin on average. This three layer assay not only will result in more nanoparticle 
labels per endoglin but also will increase the distance between the nanoparticle label and 
sensing surface. If advantageous more nanoparticle labels per endoglin over rides 
disadvantageous distance increase between nanoparticle label and the sensing surface, 
sensing signal from three layer assay will be more compared to two-layer assay on the 
GMR platform. 
The three-layer competition assay was used to detect endoglin from the 6.67 fold 
concentrated high grade prostate urine sample (4µL, WO6 52) where urinary endoglin 
competes with endoglin-biotin20 (1.66 x10
-20
 mol per sensor area, 4.15pM, 
biotin/endoglin = 20) for capture antibody (1.66 x10
-20
 mol per sensor area) on the GMR 
sensor surface followed by streptavidin-FeCo nanoparticle conjugate (41.5 pM, 1.66x10
-
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19
 mole streptavidin per sensor area, streptavidin/nanoparticle 1.3:1) binding and washing 
with water to remove unbound streptavidin-FeCo nanoparticle conjugates. The same 
experiment without competing urine sample for capture antibody on the sensor surface 
served as one control. The same experiment with endoglin instead of endoglin-biotin20 
and without competing urine sample for capture antibody on the sensor surface served as 
negative control. Three-layer assay produced 25% more signal (117 m) compared to 
two-layer assay (94 m). Streptavidin nanoparticles also don’t non-specifically bind to 
endoglin (Figure 4.21). Urinary endoglin also competed efficiently with endoglin-biotin20 
than with nanoparticle labeled endoglin. This is reasonable since nanoparticle is heavy 
and if it gets modified at the proximity of endoglin binding site to capture antibody so 
that once nanoparticle labeled endoglin binds to capture antibody, it is difficult to be 
displaced by urinary endoglin. Since biotin is small in size compared to nanoparticle, 
urinary endoglin can effectively compete and easily displace endoglin-biotin20 from the 
capture antibody binding site. Though three-layer competition assay performs better than 
two-layer competition assay, urine samples need to be concentrated for testing unless 
sensitivity is further improved. 
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Figure 4.21 Resistance changes upon binding to capture antibody modified (1.66x10
-20
 
mol capture antibody per sensor area) sensor surface  
a) magnetic nanoparticle labeled endoglin (4.15pM); c) endoglin-biotin20 (4.15pM) 
followed by streptavidin-FeCo nanoparticle conjugate (41.5 pM, 1.66x10
-19
 mole 
streptavidin per sensor area, streptavidin/nanoparticle 1.3:1) binding; e) endoglin 
(4.15pM) followed by streptavidin-FeCo nanoparticle conjugate (41.5 pM) binding. 
Resistance change due to competition of 6.66 fold concentrated urine U1 sample  
b) with magnetic nanoparticle labeled endoglin (4.15pM); d) with endoglin-biotin20 
(4.15pM) followed by streptavidin-FeCo nanoparticle conjugate (41.5 pM) binding e). 
To increase more nanoparticles per endoglin in the three-layer competition assay, two 
nanoparticle conjugations per streptavidin was sought as a solution. Since streptavidin is 
relatively little bigger molecule compared to endoglin, it will be worth to try two 
nanoparticle conjugation per streptavidin despite failure with endoglin. When we used 
harvested particles from the streptavidin two nanoparticles labeling reaction on our GMR 
sensor, signal improved minimally compared to one nanoparticle labeled streptavidin 
binding indicating that two nanoparticles cannot be attached per streptavidin due to 
comparable sizes of streptavidin and nanoparticle (Figure 4.20). The undesired 
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processing of urine samples was avoided by using 20 µL urine volume (20 nL per sensor 
area) as it provides five-fold more urinary endoglin than 4µL for three-layer competition 
assay leading to significant drop in resistance change (big sensing signal) upon 
competition. Though the more sample volume covers extra area including capture 
antibody modified area, as and when endoglin reaches the proximity of capture antibody 
due to Brownian motion, binding can happen. To test this hypothesis for two-layer assay, 
4µL nanoparticle labeled endoglin in PBS buffer, pH 7.4 (4nL and 1.66 x10
-20
 mol per 
sensor area, 4.15pM) and 20µL nanoparticle labeled endoglin in PBS buffer, pH 7.4 
(20nL and 1.66 x10
-20
 mol per sensor area, 0.83pM) binding to capture antibody (1.66 
x10
-20
 mol per sensor area) on the sensor surface was carried out. Sensing signal obtained 
by the use of 20µL sample volume corresponds to 78% of sensing signal obtained by the 
use of 4µL sample volume and this can happen mainly due to Brownian motion (Figure 
4.22).  
To test this hypothesis for three-layer assay, 4µL endoglin-biotin20 (4 nL and 1.66 x10
-
20
 mol per sensor area, 4.15 pM) and 20µL endoglin-biotin20 (20 nL and 1.66 x10
-20
 mol 
per sensor area, 0.83pM) binding to capture antibody (1.66 x10
-20
 mol per sensor area) on 
the GMR sensor surface followed by 4µL streptavidin-FeCo nanoparticle conjugate (4 nL 
and 1.66x10
-19
 mole streptavidin per sensor area, 41.5 pM) binding were carried out. 
Sensing signal obtained by the use of 20µL sample volume corresponds to 75% of 
sensing signal obtained by the use of 4µL sample volume and supports involvement of 
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Brownian motion (Figure 4.22).  Though signal drops by ~25% by the use of 20 µL 
sample volume, it provide five-fold more urinary endoglin than 4µL do for three-layer 
competition assay which will leads to significant drop in resistance change upon 
competition. 
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Figure 4.22 Resistance changes upon binding to capture antibody modified (1.66x10
-20
 
mol capture antibody per sensor area) sensor surface  
A) 4 µL magnetic nanoparticle labeled endoglin in PBS buffer (4 nL and 1.66x10
-20
 
mol per sensor area, 4.15pM); B) 20 µL magnetic nanoparticle labeled endoglin in 
PBS buffer (20 nL and 1.66x10
-20
 mol per sensor area, 0.83 pM); C) 4 µL endoglin-
biotin20 in PBS buffer (4 nL and 1.66x10
-20
 mol per sensor area, 4.15pM) followed by 
4 µL streptavidin-FeCo nanoparticle conjugate in PBS buffer (4 nL and 1.66x10
-19
 
mole streptavidin per sensor area, 41.5 pM) binding; D) 20 µL endoglin-biotin20 in 
PBS buffer (20 nL and 1.66x10
-20
 mol per sensor area, 0.83 pM) followed by 4 µL 
streptavidin-FeCo nanoparticle conjugate in PBS buffer (4 nL and 1.66x10
-19
 mole 
streptavidin per sensor area, 41.5 pM) binding.  
Based on this outcome, urine samples (20 µL; urines from patients who are biopsy 
positive for high grade prostate cancer U1-U5; low grade prostate cancer U6-U10 and 
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from individuals who are biopsy negative for cancer U11-U15) were tested as such 
without any processing under three-layer competition assay wherein 20µL urine samples 
(20nL per sensor area) competes with endoglin-biotin20 (0.83 pM, 1.66x10
-20
 mol per 
sensor area) for capture antibody on the sensor surface. All urine samples showed 
statistical significant resistance change as a sensing signal compared to control (Figure 
4.23).  
 
Figure 4.23 Resistance change due to competition of 20µL urine samples and Average 
resistance change from different grades of prostate cancer urines 
A: Resistance change due to competition of 20µL urine samples (20 nL per sensor 
area) with endoglin-biotin20 (0.83 pM, 1.66x10
-20
 mole per sensor area) followed by 
streptavidin-FeCo nanoparticle conjugate (41.5 pM, 1.66x10
-19
 mole streptavidin per 
sensor area, streptavidin/nanoparticle 1.3:1) binding  
a) control, no competing urine; b) U1; c) U2; d) U3; e) U4; f) U5; g) U6; h) U7; i) U8; 
j) U9; k) U10; l) U11; m) U12; n) U13; o) U14; p) U15.  
Columns, mean; bards, standard deviation; 6≤n≤8.  
B: Average resistance change caused by  
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i) five high grade prostate cancer urines (U1-U5); ii) five low grade prostate cancer 
urines (U6-U10); iii) five no prostate cancer urines (U10-U15); a) control. 
Encouraged by the results, as a next step to determine endoglin levels in the tested 
urine samples, dose response curve was established for three-layer competition assay. To 
have real biological environment for the dose response curve experiment, equal amounts 
of all urine samples tested are mixed to give a urine cocktail; and endoglins in the 
cocktail were depleted on a capture antibody coated silica wafer surface. Briefly a spiked 
mixture of endoglin-biotin20 (0.83 pM) and varied concentrations of pure unlabeled 
human recombinant endoglin in 20µL endoglin depleted urine cocktail was applied on 
the sensor surface to compete for capture antibody on the sensor followed by 
streptavidin-FeCo nanoparticle conjugate (41.5 pM) binding. Figure 4.24 shows the dose-
response curve of the three-layer competition assay which provides a wide detection 
range of endoglin from 27.6 fM to 83 pM with a statistically significant lower detection 
limit of 83fM.  Results from each single competing dose were compared with that of their 
immediate higher and lower competing doses as well as with the sensor background to 
arrive statistical meaning.  Our results show that the sensing signals obtained from buffer 
and endoglin depleted urine environment do not statistically differ from each other 
indicating that proteins other than endoglin in the urine do not non-specifically compete 
with endoglin-nanoparticles for capture antibody. This clearly reveals the detection 
specificity of our GMR device. 
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Urine test results from the three-layer competition assay were fitted into the dose-
response curve to deduce endoglin levels in the urine samples (Figure 4.25 (A)). Results 
show that endoglin concentration levels are significantly different between high grade 
(208±123 fM), low grade prostate cancer (79.1±57.4 fM) patients and no prostate cancer 
(45.8±28.0 fM) patient’s urine samples (Figure 4.25 (B)). 
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Figure 4.24 Three-layer competition dose response curve 
Percentage resistance change due to competition of spiked mixture of endoglin-
biotin20 (1.66x10
-20
 mol per sensor area, 0.83 pM) and varied concentrations of 
unlabeled human recombinant endoglin in 20µL endoglin depleted urine cocktail for 
capture antibody (1.66x10
-20
 mol per sensor area) on the sensor followed by 
streptavidin-FeCo nanoparticle conjugate (41.5 pM, 1.66x10
-19
 mole streptavidin per 
sensor area, streptavidin/nanoparticle 1.3:1) binding. 
Chapter 4 Application of GMR Magnetic Biosensing System 
95 
 
 
Figure 4.25 A: Endoglin levels in all the urine samples tested by three-layer 
competition assay; B: Average endoglin levels in the urine groups a) high grade 
prostate cancer (U1-U5); b) low grade prostate cancer (U6-U10); c) no prostate cancer 
(U11-U15).  
Total urinary proteins in the urine samples were determined by micro pyrogallol red 
method using a total protein kit from Sigma Aldrich. One high and one low reading 
samples for total urinary protein from each high grade, low grade and no cancer group 
were desalted using Zeba
TM
 desalting column (7K molecular weight cut-off); and total 
urinary proteins were again quantified to determine influence of urinary salts on 
pyrogallol red assay for total urinary proteins (Table 4-4). The total urinary protein 
determinations of urines before and after desalting do not differ statistically indicating 
assay is not sensitive to urinary salt contents. Endoglin levels were normalized to total 
urinary protein (TP) and remained significantly elevated in the cancer cases (Figure 
4.26). Quantitative determination of Creatinine in the urines samples were carried out 
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(Table 4-5) and endoglin levels were normalized to creatinine levels; and also remained 
significantly elevated in the cancer cases (Figure 4.26). 
Urine samples 
Total urinary proteins, 
µg/mL 
(before desalting) 
(mean±SD; n=3) 
Total urinary proteins, 
µg/mL 
(after desalting) 
(mean±SD; n=3) 
High grade prostate cancer 
U1 257.36±0.49 261.33±0.49 
U2 498.87±0.74  
U3 35.42±0.74 35.14±0.85 
U4 164.51±0.74  
U5 39.79±0.28  
Low grade prostate cancer 
U6 235.85±0.74  
U7 60.82±0.49 61.76±0.94 
U8 71.34±0.28  
U9 325.62±1.01  
U10 417.50±2.12 423.94±2.15 
No prostate cancer 
U11 378.36±0.28 384.20±0.29 
U12 279.68±1.28  
U13 132.64±0.97 134.69±0.99 
U14 310.9±1.22  
U15 140.41±0.49  
Table 4-4 Total urinary proteins before and after desalting human urine samples 
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Figure 4.26 Endoglin to total urinary protein ratio and average endoglin to total 
urinary proteins (pg/µg) in tested urine samples 
A: Endoglin to total urinary protein ratio (pg/µg) in tested urine samples;  
B: Average endoglin to total urinary proteins (pg/µg) in the urine groups  
a) high grade prostate cancer (U1-U5);  
b) low grade prostate cancer (U6-U10);  
c) no prostate cancer (U11-U15).  
Urine samples 
Creatinine levels, 
mg/mL 
(mean±SD; n=2) 
High grade prostate 
cancer 
 
U1 3.74±0.03 
U2 13.00±0.03 
U3 2.04±0.01 
U4 9.15±0.02 
U5 3.05±0.04 
Low grade prostate 
cancer 
 
U6 6.40±0.09 
U7 8.07±0.22 
U8 2.31±0.01 
U9 4.93±0.06 
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U10 1.78±0.01 
No prostate cancer  
U11 2.39±0.01 
U12 3.66±0.03 
U13 4.21±0.09 
U14 8.45±0.37 
U15 3.66±0.02 
Table 4-5 Creatinine levels in human urine samples 
 
 
Figure 4.27 Endoglin to creatinine ratio and average endoglin to creatinine (pg/mg) in 
tested urine samples 
A: Endoglin to creatinine ratio (pg/mg) in tested urine samples;  
B: Average endoglin to creatinine (pg/mg) in the urine groups  
a) high grade prostate cancer (U1-U5);  
b) low grade prostate cancer (U6-U10);  
c) no prostate cancer (U11-U15).  
4.3.4 Conclusion 
In conclusion, we have developed a novel three-layer competition-based assay on GMR 
biosensing system to detect urinary endoglin with high specificity and sensitivity using 
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unprocessed human urine samples. Our platform can detect as few as 1000 copies of the 
endoglin at concentrations as low as 83 fM. When functionalized to detect endoglin in the 
urine, our GMR biosensing system was able to successfully discriminate between patients 
with high grade cancer, and low grade cancer, and those with no cancer.  
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 External-field Free Magnetic Biosensing  Chapter 5
5.1 Introduction 
In this chapter, a new magnetic nanoparticle (MNP) detection scheme, without the 
presence of any external magnetic field, has been proposed, theoretically and 
experimentally studied. The goal is to reduce power consumption, which is critical for 
point-of-care applications. The proposed sensor structure uses a patterned groove 
structure in the biosensor so that the stray magnetic fields from the magnetic device will 
magnetize the MNPs. An example is given based on GMR sensing device with a spin 
valve structure. For this structure, the stray field from the free and pinned layer is used to 
magnetize the MNPs, located inside the groove and near to the free layer. Micromagnetic 
simulations are performed to calculate the signal level of this detection scheme. A 
maximum SNR of 40 dB from one iron oxide magnetic nanoparticle with 8 nm radius is 
obtained from the simulation. As proof of concept, GMR sensor with groove structure of 
200 nm × 200 nm was fabricated using electron beam lithography. Using this sensor, the 
detection SNR of 30 µL 30 nm magnetic nanoparticles is around 9.3 dB. This sensor 
structure is not limited to GMR device and is applicable for other spintronic and magnetic 
sensing devices such as MTJ, Hall sensor with sandwiched structure and giant magneto 
impendence (GMI). These results have been published as “External-field-free magnetic 
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biosensor”, Li, Y., Wang, Y., Klein, T. & Wang, J.-P. Appl. Phys. Lett. 104, 122401, 
(2014). 
5.2 Background and Motivation 
Bioassays that detect and quantify biomolecules at ultra-low quantity with point-of-
care settings are of great need in many fields including basic medical science, disease 
control and diagnostics, drug discovery and environment monitoring, etc. Since the first 
proposal in 199863, magnetic biosensing scheme, which combines the magnetic biosensor 
and the magnetic nanoparticle (MNP), has been intensively studied23,24,26-28,63,64,66-
68,72,82,87-90,104,105. These systems are based on the specific bond between the targeted 
biomolecule and the biologically-functionalized surface of an individual magnetic field 
sensor or a sensor-array. Functionalized MNPs are then specifically bound to these 
targeted biomolecules. Studied magnetic biosensors include GMR 
sensor23,24,63,68,72,88,90,104,105, MTJ sensor66, Hall biosensor106,107 or GMI biosensor108. The 
dipole field from the specifically bond magnetized MNPs will change the average 
magnetic field on the sensing layer of the magnetic biosensor. This causes the change of 
the magnetization configuration and consequently the transfer curve of the magnetic 
biosensor. This change can then be quantitatively correlated with the number of the 
MNPs.  Previous work has focused primarily on sensing modes that require a magnetic 
field generator, which is detrimental to the promised portability feature for magnetic 
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biosensors and also increases the power consumption of the whole system. Magnetic field 
from the bias current passed through the biosensor was proposed for magnetizing the 
MNPs109. This can eliminate the usage of the electromagnet. However, the issue for large 
power consumption still exists. A large current on sensing chip, such as tens of 
milliamperes, is required to produce a large enough magnetic field for magnetizing the 
MNPs. Such large current will not only cause Joule heating but also may result in a 
failure (electrical or mechanical) of the passivation layer between the sensor and the 
biological sample. To overcome these challenges, we propose the usage of stray field 
from the magnetic biosensor itself to magnetize the MNPs thus totally eliminate the 
usage of any external magnetic field generator (electromagnets or current lines). This 
scheme just requires a specific patterned structure, e.g. the groove, in the magnetic 
biosensor, which can be fabricated using a well-established ion milling or any other 
proper lithograph processes. 
5.3 Analytical model 
5.3.1 Conventional detection scheme 
 
In a currently available (defined as conventional in this chapter) magnetic biosensing 
scheme using a spin valve structure as shown in Figure 5.1, the MNP is biologically bond 
to the surface of magnetic biosensor. In this configuration, an external magnetic field is 
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needed so that the superparamagnetic MNP is magnetized. The magnetized MNP 
generates a dipole magnetic field, which exerts on the free layer of the spin valve. Before 
the MNP is bond to the sensor surface, the effective field      on the free layer is: 
                        
where      is the external applied magnetic field and       -        is the stray field from 
pinned layer. After bonding to the surface of the sensor, the MNP is magnetized by the 
external applied field, as well as the stray field from free and pinned layers. Both the 
stray fields from the free layer and pinned layer are very small and can be ignored for the 
conventional magnetic biosensing scheme. The magnetic charges from the free layer (two 
ends of the long axis of the sensor) are far from most of bond MNPs because of the large 
dimension of the sensor along the long axis. The magnetic charges from the fixed layer 
(two ends of the short axis of the sensor) are far from most of bond MNPs because of the 
distance from the pinned layer to sensor top surface. Due to the superparamagnetic 
property of the MNP, at external field    , its magnetization can be expressed as: 
       
                      
   
  
where    is the saturation magnetization,    is the magnetic moment of a single 
particle,    is the magnetic permeability of vacuum,      is the applied magnetic field, 
      -     is the stray field from free and pinned layer,    is the Boltzmann constant,   is 
Chapter 5 External-field Free Magnetic Biosensing 
104 
 
the absolute temperature, and   is the Langevin function. Thus, the dipole field from the 
MNP on the free layer can be written as: 
        
3(   ) 
 5
 
 
 3
 
where   is the magnetic moment of the MNP,   is space vector from the center of the 
MNP to the free layer. Therefore, the effective field on the free layer is then expressed as: 
                                
The change of      on the free layer before and after the MNP bonding will change the 
orientation of the free layer magnetization      , which leads to an electrical signal 
change of the magnetic biosensor.  
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Figure 5.1 conventional magnetic biosensing scheme 
a) Top view of a conventional magnetic biosensing scheme;  
b) Cross-section view of a conventional magnetic biosensing scheme.  
Mfree and Mpinned are the magnetization of free and pinned layers of the spin valve 
structure, respectively. Hext is the external applied magnetic field. 
 
5.3.2 External-field-free detection scheme 
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Figure 5.2 describes our proposed external-field-free detection scheme. In this 
detection scheme, a groove structure is purposely created on the magnetic sensor, so that 
the MNPs can be bond into the groove where the magnetic charges from both free layer 
and pinned layer are close to the MNP thus the stray fields from the magnetic films (free 
and pinned layer)       -     are strong. In this configuration, before the MNP bonding, the 
effective field on the free layer is only the stray field from the pinned layer, without the 
presence of the external applied field: 
                   
The MNP, after bonding into the groove, will be magnetized by the stray fields from 
both the free and pinned layers. Hence its magnetization can be expressed by: 
       
               
   
  
where       -     is the stray fields from the free and pinned layers of the magnetic 
biosensor. Combining the dipole field that generates by the MNP, the effective field on 
the free layer after the MNP bonding should be written as: 
                           
Therefore, the difference of the effective field on the free layer changes the 
magnetization configuration of the free layer. By utilizing the strong stray fields from the 
free and pinned layers to magnetize the MNP, the external applied field is no longer 
needed in this novel detection scheme. 
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Figure 5.2 External-field-free magnetic biosensing scheme 
a) Top view of an external-field-free magnetic biosensing scheme. 
b) Cross section view of an external-field-free magnetic biosensing scheme 
Mfree and Mpinned are the magnetization of the free and pinned layers of the spin valve 
structure, respectively. Hstray-film is the stray field from the free and pinned layers. 
Hdipole is the dipole field from the magnetic nanoparticle 
 
5.4 Micromagnetic simulation 
Micromagetics typically refer to the interaction of magnetic moments among materials 
with sub micrometer or nanometer scale. Compared with analytical or other simulation, 
micromagnetic simulation is often considered to be closer to the “accurate” situation. The 
basic idea of micromagnetic simulation is to divide the simulation object into many small 
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cells (typically nanometer size), then study the both individual and collective 
behavior/interaction of magnetic moment inside the small cells. The simulation is based 
on the calculation of several competing energies and their interaction, such as dipole 
energy, Zeeman energy, exchange energy and anisotropy energy. Therefore, the physical 
parameters which relate to these energy terms, such as magnetization, magnetic 
anisotropy, shape anisotropy exchange constant and damping coefficient, are critical to 
simulation results. 
In this chapter, a well-established 2-D Micromagnetic simulation software, the object-
oriented micromagnetic framework (OOMMF)
110
, is employed to simulate the 
magnetization behavior of the free layer under the stray field from the pinned layer and 
the dipole field from the MNPs. OOMMF is a free micromagnetic simulation tool 
developed by Mike Donahue, and Don Porter in Applied and Computational Mathematics 
Division (ACMD) of National Institute of Standards and Technology (NIST), which is 
written in C++ with a Tcl/Tk interface.  
Micromagnetic simulation in OOMMF employs Landau–Lifshitz–Gilbert equation for 
the divided small cell of a magnetic material
111
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where  is the magnetization of the magnetic material,      is the effective magnetic 
field,   is the electron gyromagnetic ratio,   is the damping constant and    is the 
saturation magnetization. The effective field     can be calculated as
111
 
      
 
    
  
  
 
  
    
    
 
    
   
  
         
where    is the permeability of vacuum,    is the saturation magnetization,   is 
micromagnetic energy density, which usually includes anisotropy energy density   , 
exchange constant  , applied field     , demagnetization    energy densities. In 
OOMMF simulation, all the constants and energy densities are considered to be the same 
inside the cell. The simulation of the entire object is then based on micromagnetic 
simulation of individual cells and the interaction of all the cells of the simulated object. 
5.4.1 Micromagnetic simulation without magnetic particle 
 
In OOMMF, Micromagnetic Input Format (MIF), which can be edited as a text file, is 
used as an input to the simulation. It contains all the physical parameters, such as 
saturation magnetization, exchange constant, uniaxial anisotropy, easy axis of anisotropy 
direction, demagnetization type, cell shape and size, initial magnetization direction, 
applied magnetic field, simulation converging criteria and etc.. These parameters are 
required by mmSolve2D, which is the main solver for the micromagnetic simulation. 
 Following is an example of MIF file as the input of pinned layer simulation. 
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### MATERIAL PARAMETERS 
### All units are SI. 
 
### Saturation Magnetization of the pinned layer (A/m) 
ms:1.5e+6 
 
#### Exchange constant (J/m) 
a:1e-11 
 
#### Uniaxial anisotropy (J/m
3
) 
k1:10e3 
 
#### Anisotropy type, One of <uniaxial|cubic> 
anisotropy type:uniaxial 
 
#### Initial anisotropy 
anisotropy init: constant 
 
#### Directional cosines wrt to coordinate axes. 
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anisotropy dir1:1 0 0 
 
#### Demag coefficient, dimensionless 
Damp Coef: 0.5 
 
#### Demag type, One of <ConstMag|3dSlab|2dSlab|3dCharge|FastPipe|None> 
demag type:3dslab 
 
#### Part geometry (m) 
part height:0.5e-6 
part width:3e-6 
part thickness:3e-9 
#### Part shape; in this case, part shape is defined by an external figure file 
part shape: Mask 3000_500_BG_100_100_notch.bmp 
 
#### Cell size (m) 
cell size:5e-9 
 
#### Initial magnetization direction 
init mag:uniform 90. 0. 
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#### External applied field type and range  
#### Field range specifies how magnetic field is applied to the pinned layer 
#### There are total seven parameters in the range. The first three numbers are the  
#### starting x, y, z fields in Tesla. The next three numbers are the ending x, y, z 
#### fields in Tesla. The last number specifies the steps between starting and ending 
#### fields. If the step is 0, like in this case, the ending magnetic fields are  
#### ignored, which means the only starting fields are applied through the whole  
#### simulation. In this case, a constant 0.5 T magnetic field is applied on –y direction  
#### of the pinned layer, to mimic pinned field. 
field type: uniform 
field range: 0 -0.5 0 0 -0.5 0 0 
 
#### Simulation converging criteria 
#### This is the control point of the minimum torque (|   |) acting on local  
#### magnetization. Once the minimum torque reaches this point, the simulation 
#### of each field step will be stopped. 
default control point spec: -torque 1e-6 
 
#### This is where the base output filename/format are defined 
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base output filename: archive\indcfield_3000_500_BG_100_100_notch 
magnetization output format: text %.10g 
total field output format: text %.10g 
 
#### Randomizer seed setting. If setting is 1, use seed randomize number generator 
randomizer seed:1 
 
In the simulation, both free and pinned layer with a groove structure are divided into 
small magnetic cells with the same size (5 nm). Each magnetic cell has its own magnetic 
moment and interacts with all other cells. For free layer, no external magnetic field is 
applied to it; while for pinned layer, a 0.5 T external magnetic field is set in MIF to 
mimic the pinning field from antiferromagnetic (AFM) layer.  
Typically in MIFG file, the part shape defines the shape of the simulation object, and 
part geometry defines the dimensions. However, due to the irregular shape of groove 
structure sensor, the part shape and dimensions of this simulation are defined by external 
bmp files with different groove sizes. Figure 5.3 shows the definition of the dimensions 
for the sensor with a groove structure. In the OOMMF simulation, the size of the 
magnetic biosensor is fixed at 3 µm long (Ls) by 0.5 µm wide (Ws), while the groove 
dimension (length Lg and width Wg) varies for optimization. Both free and pinned layer 
share the same part geometry and dimensions. 
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Figure 5.3 Top view of magnetic biosensor with groove structure. 
Ls and Lg are the length of the magnetic biosensor and groove, respectively. Ws and 
Wg are the width of the magnetic biosensor and groove, respectively. 
 
In this simulation, there are two types of simulation result outputs are being 
used/processed. One is .omf for magnetization vector file. OMF file is in vector field 
format (OVF), which contains local magnetization vector quantities of each cell. Figure 
5.4 shows magnetization vector distribution of pinned layers with different size groove 
structures ( a) 100 nm   100 nm groove structure; b) 100 nm   200 nm groove structure; 
c) 100 nm   400 nm groove structure; d) 100 nm   600 nm groove structure)). They are 
just four examples of various groove structures in this simulation. Around the edge of the 
groove structures, it looks like the magnetization vectors are aligned with other bulk 
magnetization vectors. However, if we look into the detail, which is shown in Figure 5.5, 
the magnetization vectors of individual cell around the groove edge have some deviations 
from magnetization vectors in bulk structure. This is due to the energy competition 
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between demagnetization field and the strong pinning field (0.5T) defined in the MIF 
input files. There is no external applied magnetic field in all the simulation here.  
The other output file is .ohf file. OHF contains local magnetic field vectors in spiral 
positions. Figure 5.6 shows the magnetic field vector distribution on free layer position 
from pinned layer. Each magnetic field vector is the sum of magnetic stray fields 
originating from all the magnetizations on pinned layer, as shown in Figure 5.4. It can be 
noticed that magnetic fields also exist in the groove structure. Therefore, the stray fields 
from pinned layer need to be considered during the simulation of magnetic fields applied 
on the magnetic particle. Not only is ohf an output from OOMMF simulation, but also 
can it be treated as an input to OOMMF simulation. In OOMFF input definition file MIF, 
the external applied field can be defined from an ohf file, which defines a local magnetic 
field on each cell. Figure 5.7 demonstrates magnetization vector distribution of free layer 
with different groove structure sizes. There is no real external magnetic field applied, 
however, free layer is affected by the stray field from pinned layer. Therefore, magnetic 
field vectors of pinned layer, as shown in Figure 5.6, are used as the input to simulate the 
magnetization of free layer. As shown in Figure 5.7, the free layer magnetization vectors 
tend to align to the long axis of the sensor, which is defined by the competition of the 
shape anisotropy and the stray field from pinned layer. 
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Figure 5.4 Pinned layer magnetization vector distribution with different groove 
structure sizes. 
Arrow subsample: 10; view from +z direction 
a) 100 nm   100 nm groove structure; b) 100 nm   200 nm groove structure; c) 100 
nm   400 nm groove structure; d) 100 nm   600 nm groove structure 
 
Figure 5.5 Zoom in view of 100 nm   100 nm groove structure edge of pinned layer 
magnetization vector distribution 
Arrow subsample: 1; view from +z direction 
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Figure 5.6 Magnetic field vector distribution on free layer from pinned layer with 
different groove structure sizes 
Arrow subsample: 10; Data scale: 0.181 A/m 
a) 100 nm   100 nm groove structure; b) 100 nm   200 nm groove structure; c) 100 
nm   400 nm groove structure; d) 100 nm   600 nm groove structure 
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Figure 5.7 Free layer magnetization vector distribution with different groove structure 
sizes  
Arrow subsample: 1; view from +z direction 
a) 100 nm   100 nm groove structure; b) 100 nm   200 nm groove structure; c) 100 
nm   400 nm groove structure; d) 100 nm   600 nm groove structure; e) 200 nm   
100 nm groove structure; f) 200 nm   200 nm groove structure; g) 200 nm   400 nm 
groove structure; h) 200 nm   600 nm groove structure 
5.4.2 Micromagnetic simulation with magnetic particle 
 
In general, the detection signal of MNP using groove structure sensor, is computed 
from the averaged magnetization distribution of free layer with and without the existence 
of MNP. The detail micromagnetic process is listed in Figure 5.8. The pinned layer 
magnetization vectors and magnetic field vectors on the free layer are firstly calculated 
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by OOMMF. While for free layer, before the MNP bonding, the effective field is the sum 
of the stay fields from all the magnetic cells of the pinned layer. Therefore, the free layer 
magnetization without MNP can be calculated, using pinned layer magnetic stray field as 
the external field in OOMMF. With the MNP sitting in the groove, we assume the center 
of the MNP is the same level with the center of the free layer as shown in Figure 5.2 (b). 
The MNP is magnetized by the total field from all the magnetic cells of the free and 
pinned layers. The dipole field from the MNP is discretized and incorporated into the 
OOMMF input file as well as the stray field from the pinned layer on the free layer. So, 
with the existence of MNP, the averaged magnetization orientations of the free layer are 
computed from the magnetization distribution of the magnetic cells by OOMMF.  
5.5 Micromagnetic Simulation Results 
In this section, a single commercial available iron oxide MNP is simulated to explore 
the maximum sensitivity of this scheme while the MNP resides at the center of the 
groove structure. The iron oxide MNP has saturation magnetization value of 480 
emu/cm
3
 and radius of 8 nm. The signal from the MNP is represented by the change of 
the magnetoresistive ratio (MR) with and without the presence of the MNP. Figure 5.9 
and Figure 5.10 show the MR change due to the MNP for different groove dimensions. In 
Figure 5.9 and Figure 5.10, the width of the groove is fixed at 100 nm and 200 nm, 
respectively, while the length of the groove varies from 100 nm to 700 nm. As shown in 
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Figure 5.9, the signal is at the maximum when the groove length is 100 nm in this 
simulation. It indicates stronger stray field from both the free and pinned layers acting on 
the MNP and stronger interaction between MNP dipole field the free layer. The signal 
then decreases rapidly to the minimum with 200 nm groove length and increases as the 
length increases, suggesting a complicated interaction among the free/pinned stray fields, 
MNP dipole field and free layer. Figure 5.10 shows a maximum signal (8.9 × 10
-5
) with 
100 nm groove length structure in this simulation. The signal then decreases dramatically 
with 200 nm groove length and increases slowly with a longer groove structure. In 
comparison, for a sensor with groove length longer than 200 nm, the sensor with 200 nm 
groove width shows a more stable signal change than 100 nm width case. This is possibly 
due to the reduced magnetic material left on the magnetic biosensor. Compared with 
experimental data
112
, which shows a noise level around 10
-5
 MR change using a spin 
valve biosensor, a maximum sensitivity (around 40 dB) of ten nanoparticles detection can 
be achieved using our detection method. 
5.6 Detection of magnetic nanoparticle using external-field free sensor 
As proof of concept, a GMR sensor with groove structure of 200 nm × 200 nm was 
fabricated using electron beam lithography, and based on this sensor, real time detection 
of 30 µL magnetic nanoparticles (30 nm in diameter) was demonstrated. 
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Figure 5.8 Micromagnetic simulation flow of detection signal of magnetic biosensor 
with groove structure  
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Figure 5.9 The signal from one 8 nm radius iron oxide magnetic nanoparticle, in terms 
of magnetoresistive ratio (MR) change, of biosensor with 100 nm groove width and 
different groove length 
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Figure 5.10 The signal from one 8 nm radius iron oxide magnetic nanoparticle, in 
terms of magnetoresistive ratio (MR) change, of biosensor with 200 nm groove width 
and different groove length 
5.6.1 External-field free sensor fabrication 
The fabrication of external-field free sensor is based on the fabrication of stripe 
sensor, which is described in chapter 4. The extra one step is to put groove structure on 
the stripe sensor before ion milling, using electron beam lithography due to the sub-
micrometer size of groove structure and the width of stripe sensor. In electron beam 
lithography process, the key is the alignment between the groove structure and the stripe 
sensor. As proof of concept, a GMR sensor with groove structure of 200 nm × 200 nm 
was fabricated using electron beam lithography, and based on this sensor, real time 
detection of 30 µL magnetic nanoparticles (30 nm in diameter) was demonstrated. Figure 
5.11 shows the schematic mask drawing of 200 nm × 200 nm groove pattern on top of 
500 nm width GMR sensor strip, for electron beam lithography patterning. In order to 
improve the alignment between the groove structures and GMR stripes, one extra line of 
groove structures was patterned in the middle of two GMR sensor stripes.  
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Figure 5.11 Schematic mask drawing of GMR sensor with groove structure for 
electron beam lithography 
The electron beam patterning procedure is listed in the following steps: 
1) Pre-bake 250C, 5min  
2) Spin coating with PMMA-C9, 3500 rpm, 45sec  
3) Softbake 180C, 2min 
4) Pattern definition by electron beam lithography 
5) Check on the microscope for nanoholes  
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6) Ionmill etch, etch for stack thickness (10 degree for 3x3mins, 60 degree for 
1x3mins, beam current around 84mA ) 
7) Lift-off the PMMA: NMP 150C, 1hour + ultrasonic (10 mins). 
Figure 5.12 is the optical image (100X) of GMR sensor with 200 nm × 200 nm groove 
structure after electron beam lithography.  
 
Figure 5.12 optical image (100X) of GMR sensor with 200 nm × 200 nm groove 
structure 
5.6.2 Real time magnetic nanoparticle detection 
Magnetic nanoparticles were detected using the GMR sensor with groove structures. 
Figure 5.13 shows real time detection of 30 µL 30 nm magnetic nanoparticle (1mg/mL), 
using GMR sensor with 200 nm × 200 nm groove structure. Before adding any DI water 
and magnetic nanoparticles, a baseline of detection was first established only by applying 
AC current through GMR sensor. Then 10 µL DI water was added on top of both active 
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and control sensors, where sensor signal stayed relatively unchanged as expected. The 
control sensor was covered by a two-component epoxy, to isolate sensor and particles. 
Finally, 30 µL solution of 30 nm magnetic nanoparticle (1mg/mL) was spotted onto the 
top of GMR sensor, which generated about 50 µV sensor signal. Since the noise level of 
the active sensor is around 17 µV, the SNR of the detection is around 9.3 dB. 
 
Figure 5.13 Real time detection of 30 µL 30 nm magnetic nanoparticle (1mg/mL), 
using GMR sensor with 200 nm × 200 nm groove structure 
5.7 Conclusion 
In summary, an external-field-free magnetic biosensing structure is demonstrated, 
which is useful for magnetic biosensing system miniaturization (e.g. handheld) and 
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power consumption control. The structure is based on a unique patterned grooves 
embedded in the magnetic biosensor and employs the stray fields from the free and 
pinned layers of the magnetic biosensor for MNP magnetization. Micromagnetic 
simulations were carried out for a theoretical study of this detection scheme. Signals from 
different groove structures were calculated. The results showed a maximum SNR of 18.6 
dB from one 8 nm radius iron oxide magnetic nanoparticle locating in the center of the 
groove structure. The signal strength increased with the MNP position near the groove 
corner. In addition, the dynamic detection range of this detection scheme was explored by 
simulating the signal from multiple nanoparticles in the groove structure. The simulation 
showed that uniformly distributed 500 nanoparticles did not saturate the sensor signal and 
the maximum detection limit of this detection scheme was determined by the physical 
accommodation of nanoparticles in the groove structure. Finally, the real time detection 
of magnetic nanoparticles was demonstrated experimentally, by a GMR sensor with 200 
nm × 200 nm groove structure. The sensor signal is around 50 µV within 10 minutes for 
the detection of 30 nm magnetic nanoparticles (1mg/mL), for which the estimated 
landing number of MNPs is 220/μm 26. 
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 Summary Chapter 6
In this dissertation, a magnetic biosensing system, based on the combination of GMR 
magnetic biosensor and high moment magnetic nanoparticle, is proposed, fabricated and 
demonstrated. 
The prototype of GMR biosensing sensor has been designed and fabricated through 
photolithography technique. Comparing with conventional linear GMR sensor, a 
hysteresis GMR sensor with zero ground state of magnetization between free and fixed 
layer, is demonstrated. The new hysteresis GMR sensor shows higher sensitivity under a 
lower required magnetic applied field.  
Together with the high moment FeCo magnetic nanoparticle, the magnetic biosensor 
has been applied to the detection of various biomolecules/biomarkers. We demonstrated 
the accurate quantification of human IL-6 by sandwich approach. This magnetic 
biosensing system is able to quantify as low as 200 molecules of human IL-6,. The low 
signal level of the control sensors suggests no significant non-specific binding using this 
sensing scheme. Moreover, a linear trend, between the sensing signal and the number of 
IL-6 molecules on the sensor surface, which suggests the application of GMR biosensing 
system for quantifying very small amount of the biomarker in the biological sample. In 
addition, the difference of IL-6 concentrations in human serum samples is nicely 
identified by the magnetic biosensing system. The accurate detection of various endoglin 
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concentrations in human urine samples, match with the grades of patent’s prostate cancer, 
which suggests endoglin, is potentially a good biomarker candidate for prostate cancer. 
In the last part of the thesis, an external-field free magnetic biosensing system is 
demonstrated. The external-field free magnetic biosensor utilizes the magnetic stray field 
from free and fixed layer of GMR sensor, to magnetize the magnetic labels. 
Micromagnetic simulation is performed to calculate different sensitivities for various 
dimensions of sensor design. At last, the real time detection of magnetic nanoparticle 
based on the external-field free sensor is demonstrated. 
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